U.S. patent application number 12/205327 was filed with the patent office on 2009-02-19 for rna interference using a universal target.
This patent application is currently assigned to Myriad Genetics, Incorporated. Invention is credited to Liwen Huang, Herbert L. Ley, III.
Application Number | 20090048111 12/205327 |
Document ID | / |
Family ID | 39734319 |
Filed Date | 2009-02-19 |
United States Patent
Application |
20090048111 |
Kind Code |
A1 |
Huang; Liwen ; et
al. |
February 19, 2009 |
RNA INTERFERENCE USING A UNIVERSAL TARGET
Abstract
The present invention provides novel methods for manipulating
levels of expression of gene products using RNA interference
(RNAi). The methods disclosed can be used to investigate gene
function, to create disease-resistant organisms, and to treat
disease.
Inventors: |
Huang; Liwen; (Sandy,
UT) ; Ley, III; Herbert L.; (Salt Lake City,
UT) |
Correspondence
Address: |
MYRIAD GENETICS INC.;INTELLECUTAL PROPERTY DEPARTMENT
320 WAKARA WAY
SALT LAKE CITY
UT
84108
US
|
Assignee: |
Myriad Genetics,
Incorporated
Salt Lake City
UT
|
Family ID: |
39734319 |
Appl. No.: |
12/205327 |
Filed: |
September 5, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10680449 |
Oct 6, 2003 |
7422853 |
|
|
12205327 |
|
|
|
|
60416353 |
Oct 4, 2002 |
|
|
|
Current U.S.
Class: |
504/241 ;
435/419; 800/279 |
Current CPC
Class: |
C12N 2320/12 20130101;
C12N 15/111 20130101 |
Class at
Publication: |
504/241 ;
435/419; 800/279 |
International
Class: |
A01N 43/90 20060101
A01N043/90; C12N 5/04 20060101 C12N005/04; C12N 15/82 20060101
C12N015/82 |
Claims
1. A method of reducing the endogenous expression of a plurality of
gene products in cells or organisms that exhibit transitive RNA
interference comprising: providing a plurality of expression
cassettes that direct the expression of recombinant transcripts,
each transcript having a unique nucleotide sequence encoding an
individual gene product and a universal RNA interference target
sequence that is 3' of, and adjacent to, said unique nucleotide
sequence encoding an individual gene product, creating a plurality
of transfected test cells by introducing said expression cassettes
into cells capable of transcribing and translating the encoded
individual gene products, and introducing an RNA into said
transfected test cells, said RNA being capable of inducing RNA
interference by specifically targeting the universal RNA
interference target sequence shared by the recombinant transcripts;
whereupon the expression of all recombinantly expressed gene
products is reduced by a primary RNA interference response, and the
expression of homologous endogenously expressed gene products is
reduced by a transitive RNA interference response.
2. The method of claim 1, wherein the step of introducing said RNA
is by way of introducing a DNA that directs the in vivo
transcription of said RNA.
3. The method of claim 2, wherein the RNA transcribed in vivo is a
small hairpin RNA.
4. The method of claim 1, wherein the step of introducing said RNA
is by way of introducing an RNA synthesized in vitro.
5. The method of claim 4, wherein the RNA synthesized in vitro is a
small single-stranded hairpin RNA.
6. The method of claim 4, wherein the RNA synthesized in vitro is a
double-stranded siRNA.
7. The method of claim 1, wherein said universal RNA interference
target sequence is located in the 3' untranslated region of the
recombinant transcript.
8. The method of claim 1, wherein said universal RNA interference
target sequence encodes a peptide, is cloned in frame with the 3'
end of said nucleotide sequence encoding an individual gene
product, and results in the expression of a fusion protein.
9. A method of treating a disease in plants caused by an infectious
agent comprising the steps of: administering to a plant in need of
such treatment an expression cassette comprising a nucleotide
sequence encoding a gene product of said infectious agent and a
universal RNA interference target sequence, and introducing into
the plant an RNA that induces RNA interference of expression of
said gene product of said infectious agent by targeting said
universal RNA interference target sequence.
10. The method of claim 9, wherein the step of introducing said RNA
that induces RNA interference is by way of introducing a DNA that
directs the in vivo transcription of the RNA.
11. The method of claim 10, wherein the RNA transcribed in vivo is
a small hairpin RNA.
12. The method of claim 9, wherein the step of introducing said RNA
that induces RNA interference is by way of introducing an RNA
synthesized in vitro.
13. The method of claim 12, wherein the RNA synthesized in vitro is
a small single-stranded hairpin RNA.
14. The method of claim 12, wherein the RNA synthesized in vitro is
a double-stranded siRNA.
15. The method of claim 12, wherein the RNA synthesized in vitro is
enzymatically synthesized.
16. The method of claim 12, wherein the RNA synthesized in vitro is
chemically synthesized.
17. The method of claim 9, wherein said disease is a viral
infection and said infectious agent is the virus that causes said
viral infection.
18. The method of claim 9, wherein said disease is a fungal
infection and said infectious agent is the fungus that causes said
fungal infection.
19. The method of claim 9, wherein said disease is caused by
nematodes and said infectious agent is the nematode that causes the
disease.
20. A method of imparting on plants a resistance to a pathogen
comprising the steps of: administering to a plant in need of
resistance to a pathogen an expression cassette that directs the
expression of a chimeric RNA comprising a nucleotide sequence
encoding a gene product of said pathogen, or a portion thereof,
operably linked to a universal RNA interference target sequence,
and introducing into the plant an RNA that induces RNA interference
of expression of said gene product of said pathogen by targeting
said universal RNA interference target sequence.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 10/680,449, filed Oct. 6, 2003 (now U.S. Pat.
No. 7,422,853), which claims benefit under 35 U.S.C. .sctn. 119(e)
of U.S. Application Ser. No. 60/416,353, filed Oct. 4, 2002; the
disclosures of both of which are hereby incorporated by reference
in their entirety.
FIELD OF THE INVENTION
[0002] The present invention generally relates to the field of
research into gene product function, and also disease etiology. It
describes a method for altering the levels of expression of gene
products that can be used in cells, both in culture and in
situ.
BACKGROUND OF THE INVENTION
[0003] The interference of expression of specific genes following
the introduction of double-stranded RNAs (dsRNAs) of corresponding
sequence has been observed in a variety of organisms. Initially
described as the post-transcriptional gene silencing (PTSG) of
transgenes in transgenic plants, similar dsRNA-dependent gene
silencing has now been observed in protozoa, fungi, nematodes,
insects, and mammals, and the phenomenon is now generally referred
to as "RNA interference."
[0004] RNA interference (RNAi), which has been defined as the "the
process of sequence-specific, post-transcriptional gene silencing
in animals and plants, initiated by double-stranded RNA (dsRNA)
that is homologous in sequence to the silenced gene" (Elbashir, et
al., Nature 411: 494-498 (2001)), has also been described as "the
process whereby dsRNA induces the sequence-specific degradation of
homologous mRNA" (Chiu & Rana. Molecular Cell 10:549-561
(2002)). Many of the mechanistic details of RNAi first came to
light from studies in which long dsRNAs matching the sequences of
specific target gene transcripts were introduced into the nematode
worm, Caenorhabditis elegans (Fire et al., Nature 391:806-811
(1998)). These early studies inspired many more experiments to be
conducted in a variety of organisms, and it is now clear that
homologous machinery for RNAi is widely distributed among
eukaryotic organisms, including mammals. Although initial attempts
to provoke RNAi in mammals and mammalian cells with long dsRNAs
failed, it was later determined the failures occurred because such
RNA molecules activate an antiviral response that leads to a
general inhibition of translation and ultimately cell death.
Subsequent studies in a variety of non-mammalian species
demonstrated that long dsRNAs introduced into cells are
enzymatically cleaved into shorter duplexes comprising two
complementary single-stranded RNAs of .about.21-25 nucleotides (see
Sharp, Genes & Dev. 15:485-490 (2001), and references therein).
More recent studies have demonstrated that, while dsRNAs of 30
basepairs or more elicit the aforementioned antiviral response, RNA
duplexes comprising two complementary single-strands of 21
nucleotides each, which pair to form a 19 basepair duplexed region
with two nucleotide 3' overhangs (so called small or short
interfering RNAs (siRNAs)), can mediate RNAi in cultured mammalian
cells without evoking an antiviral response (Elbashir et al.,
Nature 411:494-498 (2001)). Additionally, when appropriately
targeted via their nucleotide sequence, these siRNAs can
specifically suppress the expression of both endogenous genes and
heterologous transgenes, of corresponding sequence. Even more
recent studies have demonstrated that while double-stranded siRNAs
are very effective at mediating RNAi in a variety of cell types,
short, single-stranded, hairpin-shaped RNAs can also mediate RNAi,
presumably because they are processed into siRNAs by cellular
enzymes (Sui et al., Proc. Natl. Acad. Sci. U.S.A. 99:5515-5520
(2002); Yu et al., Proc. Natl. Acad. Sci. U.S.A. 99:6047-6052
(2002); and Paul et al., Nature Biotech. 20:505-508 (2002)). This
discovery has significant and far-reaching implications since the
production of such small hairpin RNAs (shRNAs) can be readily
achieved in vivo by transfecting cells with transcription vectors
bearing short inverted repeats separated by a small number of
(e.g., six) nucleotides. Additionally, if features are included to
ensure the stability of the transcription plasmid, or direct the
integration of the transcription cassette into the host cell
genome, the RNAi induced by the encoded shRNAs, can be made stable
and heritable.
[0005] Since it was first exploited to silence specific genes in C.
elegans, RNAi has become an irreplaceable tool for molecular,
cellular and developmental biologists seeking to discover the
functions of specific genes. Although few of the molecular
mechanisms of RNAi are known in detail, it is clear that the
degradative process involves the assembly of a multisubunit
ribonucleoprotein nuclease complex, known as RISC (for RNA-induced
silencing complex), which is somehow guided by the antisense strand
of an siRNA to a complementary target sequence in a mature RNA
transcript, where it catalyzes the cleavage of the targeted
transcript. It is also clear that all that is necessary to target a
transcript for degradation is that the sequence of the antisense
strand of an siRNA be complementary to that of a "target sequence"
in the transcript to be degraded. Empirical studies have shown,
however, that not all target sequences are equivalent. That is,
siRNAs corresponding to different target sequences within the same
transcript can exhibit significantly different efficiencies in
directing the degradation of the same transcript. Furthermore, at
present it is impossible to predict which target sequences will
prove to be most effective targets. Practically, if one wants to
efficiently silence a particular gene by RNA interference, one must
empirically determine which sequences make the best targets by
designing and testing siRNAs corresponding to different target
sequences. This process is both cumbersome and time consuming.
[0006] In all taxa exhibiting RNAi, siRNAs corresponding to a
specific target sequence in a gene or transgene (primary siRNAs or
trigger siRNAs), evoke a "primary" RNAi response, wherein the
targeted transcript is cleaved in the region of nucleotide sequence
complementary to the antisense strand of the siRNA. However, in C.
elegans and plants, a "secondary" RNAi response is observed,
wherein "secondary" siRNAs are produced that direct cleavage of the
target transcript in regions outside of the original target
sequence. In C. elegans, these secondary cleavages occur at sites
exclusively 5' of the primary siRNA target sequence, but in plants,
these secondary cleavages occur at sites either 5' or 3' of the
primary siRNA target sequence. Additionally, if the regions of
nucleotide sequence in which secondary RNAi cleavages occur are
homologous to other transcripts within the cell, the secondary RNAi
response can lead to silencing of transcripts containing highly
similar nucleotide sequences, that were not initially targeted by
the trigger siRNA. The observed secondary RNAi response has been
termed "transitive RNAi," because the sites of cleavage during the
secondary response transit along the originally targeted transcript
away from the primary target to adjacent regions, or the silencing
transits to transcripts that were not initially targeted during the
primary RNAi response.
[0007] Although the specific mechanisms operating behind the
phenomenon of transitive RNAi remain to be elucidated, the taxa
that exhibit transitive RNAi also appear to be able to "amplify"
the gene silencing response induced by primary siRNAs.
Additionally, it has been shown that in Arabadopsis and C. elegans,
transitive RNAi requires the action of putative RNA-dependent RNA
polymerases (RdRPs) (Dalmay et al., Cell 101:543-553 (2000) and
Sijen et al., Cell 107:465-476 (2001)). Consequently, it has been
hypothesized that in C. elegans, transitive RNAi involves an
amplification step catalyzed by RdRP, whereby the antisense strand
of siRNAs serve as primers for synthesis of dsRNAs by RdRP, using
the targeted transcript as the template, and the nascent dsRNAs are
subsequently cleaved by an endonuclease (Dicer) to produce
secondary siRNAs (Sijen et al., Cell 107:465-476 (2001). If the
nascent dsRNA so synthesized contains nucleotide sequences highly
similar to nucleotides sequences in RNA transcripts not targeted by
the initial siRNA during a primary RNAi response, the dsRNA
corresponding to these nucleotide sequences will be cleaved to form
the "secondary" siRNAs necessary to target these alternate
transcripts and transit the silencing to the gene products encoded
by these alternate transcripts. This hypothesis is consistent with
the observation that, in some studies, siRNAs designed to target a
particular member of a gene family, ultimately induced silencing of
the entire family of genes.
[0008] Although RNAi has proven to be a remarkably powerful tool
for investigating gene function in a variety of taxa, as mentioned
above, Tuschl and colleagues only recently discovered that
21-nucleotide siRNAs could be used for studying gene function in
mammalian cells without evoking a general antiviral response
(Elbashir et al., Nature 411:494-498 (2001)). Unfortunately, once a
gene is selected for siRNA-induced silencing, the choice of which
sequences to target by siRNAs is somewhat unclear. Towards this
end, Holen and colleagues investigated the efficacy of siRNAs
targeted to different positions in the transcript of human
coagulation trigger Tissue Factor (hTF) in a variety of human cell
types in culture (See Holen et al., Nucleic Acids Res. 30:1757-1766
(2002)). In this study several siRNAs corresponding to several
target sequences located in hTF transcripts were synthesized and
tested for their ability to induce silencing of the hTF gene. Of
the several siRNAs synthesized and tested only a few resulted in a
significant reduction in expression of hTF, suggesting that
accessible siRNA target sites may be rare in some human mRNAs.
Further, siRNAs targeting different sites in the hTF mRNA
demonstrated striking differences in their ability to silence the
expression of hTF. Although, strong positional effects were seen
with the siRNAs tested, and regions of high GC content seem to be
targeted less efficiently than those of low GC content, Holen and
coworkers concluded that the factors determining the differences in
siRNA efficiency remain unclear, and that susceptible RNAi target
sites in some human genes may be rare.
[0009] From a practical perspective, the results of Holen and
colleagues suggest that it is difficult, if not impossible to
predict, a priori, what sequences to target in a gene to target
with siRNAs to induce efficient silencing by RNAi. In addition,
there is a growing body of evidence that specific siRNAs selected
to silence particular genes may produce unwanted and unanticipated
"off-target" effects--altering the expression of untargeted RNA
transcripts. Jackson and colleagues recently published the results
of a study of off-target gene regulation conducted using a gene
expression profiling technique to characterize the specificity of
gene silencing by siRNAs in cultured human cells. Their results
provide clear evidence that treatment of cells with siRNAs
corresponding to different sequences within the same RNA transcript
may result in different, but reproducible, off-target silencing
effects, at least some of which may be due to partial sequence
homology between the affected transcripts and either the sense or
the antisense strand of the siRNA employed. They conclude that it
may be difficult to select an siRNA sequence that will be
absolutely specific for the target of interest (Jackson et al.,
Nature Biotech. 21:635-637 (2003)).
[0010] Recent advances in genomics, especially with the completion
of the human genome sequence, have lead to the discovery of
numerous novel genes of unknown function. Unfortunately, advances
in our ability to sequence genomes, and identify novel genes within
them have far outstripped our ability to determine the function of
the gene products of these novel genes. Classically, gene function
has been addressed in vivo by two distinct approaches:
overexpression of the gene product and underexpression of the gene
product.
[0011] High-throughput methodology in biotechnology is largely
responsible for the recent explosive growth of knowledge in
genomics and proteomics--two specialty fields that are relatively
new to the larger field of molecular biology. In the realm of
pharmaceutical research and development, high-throughput
technologies, genomics and proteomics, have had a profound impact
on therapeutic drug development (Kennedy. EXS. 89:1-10 (2000)).
Such technologies have issued in a "new millennium" of drug
discovery (Cunningham. J. Pharmacol. Toxicol. Methods. 44:291-300
(2000)), and have provided a catalyst for change in drug discovery
paradigms (Hanke. J. Law Med. Ethics. 28(4 Suppl):15-22 (2000)).
Such technologies have the potential for greatly increasing the
speed of drug development, and for reducing the associated
costs--both of these factors being critically important given the
current economic and social climate. Clearly, significant
improvements in the ability of research scientists to (a)
selectively overexpress specific target genes, (b) selectively
block the expression of specific target genes, (c) screen large
numbers of target genes for their cellular functions, and (d)
ultimately determine how overexpression or underexpression of
specific target genes affect desired outcomes in mammalian cells,
will be of benefit to society.
[0012] Traditionally, RNAi has been applied to investigate the
function of genes in a one-target-at-a-time mode. This approach has
proven very useful in analyzing the function of a limited number of
genes in the model organisms C. elegans and D. melanogaster. The
use of microarray-based RNAi technology using siRNAs should greatly
facilitate the investigation of functions for hundreds or thousands
of mammalian genes simultaneously in a parallel fashion. However,
given the findings of Holen et al. and Jackson et al., discussed
above, the choice of what specific sequence within an mRNA to
target with siRNAs of corresponding sequence is completely unclear.
Further, although microarray-based RNAi technology will perhaps
allow the empirical identification of sequences that will serve as
ideal targets of RNAi, the process of synthesizing and testing
numerous siRNAs is laborious and costly.
[0013] While RNAi holds much promise for high-throughput analyses
designed to determine gene function through the silencing of large
numbers of genes, the method is not without complications and
challenges. Perhaps the most fundamental challenge is how to pick a
target sequence within the target transcript that will allow for
the efficient silencing of the target gene, along with minimal
unintended and undesired off-target effects. Despite numerous
studies in which siRNAs have been employed to induce gene
silencing, no definitive rules have evolved to assist researchers
in picking the most effective sequences to target within a given
transcript. Although there are general guidelines to help
researchers narrow their choices for target sequences, researchers
must still use a trial and error approach to empirically determine
what individual siRNAs work best, and what siRNAs have minimal
off-target effects. Given these limitations and the many potential
and varied applications of RNAi, there is a clear need for
alternative approaches and techniques for altering gene expression
by siRNAs, especially with regards to high-throughput
applications
BRIEF SUMMARY OF THE INVENTION
[0014] The present invention provides novel methods for altering
levels of expression of a plurality of gene products using RNA
interference (RNAi) induced by a "Universal interfering RNA"
(UiRNA) directed towards a commonly-shared "Universal target RNA"
(UtRNA). The UtRNA, which is incorporated into a plurality of
chimeric RNA transcripts, each comprising a different subject RNA,
whose cellular concentration is to be decreased, may be located at
several locations within the chimeric transcripts, depending upon
the application. In addition, when the subject RNAs encode
polypeptides, a UtRNA encoding a readily detectable peptide (e.g.,
epitope tag, fluorescent peptide, enzymatic tag, etc.) can be
chosen and cloned in-frame with the subject RNAs such that fusion
proteins are produced by translation of the chimeric RNA
transcripts. Advantageously, such a UtRNA-encoded peptide tag can
be used to readily quantitate the level of expression of the fusion
proteins under study. The methods of the present invention can be
readily employed to investigate the function of any number of gene
products, and the more gene products being investigated, the
greater the benefits of the methods. Preferably the method is
employed to selectively manipulate the expression levels of a
plurality of distinct gene products in cultured target cells, in a
parallel, high-throughput, format.
[0015] Importantly, the expression of all gene products encoded by
chimeric RNA transcripts bearing a common UtRNA can be manipulated
through RNAi induced by the same UiRNA, which is specifically
designed to target the UtRNA. As such, the UiRNA can be a
double-stranded siRNA, or a single-stranded shRNA. Furthermore, the
UiRNA can be introduced into the target cells by any of the various
means known in the art. In one set of embodiments, introduction of
the UiRNA is by way of a DNA that directs the in vivo transcription
of an RNA, or RNAs within the target cells or organisms. In certain
embodiments the in vivo transcribed RNA can be a small hairpin RNA
(shRNA) that is processed by cellular ribonucleases (RNases) to
produce an siRNA-like UiRNA. In other embodiments, two
complementary siRNAs can be transcribed in-vivo, and annealing of
the two individual strands results in the formation of a
double-stranded siRNA-like UiRNA. In some of these embodiments the
DNA that directs the in-vivo expression of the UiRNA is introduced
into the target cells or organisms before the introduction of
expression vectors directing the expression of the chimeric RNA
transcripts. In certain of these embodiments, an expression
cassette--and preferably an inducible expression cassette--is
stably introduced into the target cells or organisms to produce
transgenic target cells or organisms that can express UiRNA when
required to do so. In another set of embodiments, the UiRNA is
synthesized in vitro and subsequently introduced to the target
cells. Such in vitro synthesized UiRNA may be chemically or
enzymatically synthesized and may be the double-stranded UiRNA
itself, or may be an shRNA that is processed by RNases, in vivo or
in vitro, to produce the UiRNA.
[0016] The UtRNA can be composed of any sequence of nucleotides
that facilitates the efficient RNAi of all chimeric RNA transcripts
in which it appears, regardless of where it occurs within the
transcript, and regardless of what target RNA is included in the
same transcript. In one set of embodiments, the UtRNA is placed in
a non-coding region of the chimeric RNA transcript--either the 5'
untranslated region (UTR), or the 3' UTR. In another set of
embodiments, the UtRNA encodes a peptide and is inserted in-frame
with the coding region of the target RNA--either in-frame with
either end of the coding region, or within the coding region
itself--thereby creating a chimeric open reading frame that is
translated into a fusion protein. In this set of embodiments, the
UtRNA preferably encodes a peptide, which can be used to detect and
quantitate the level of expression of the fusion protein.
[0017] Advantageously, the methods of the present invention provide
a means for targeting a plurality of recombinantly expressed gene
products for RNA interference, by providing a plurality of
expression vectors that direct the expression of a plurality of
chimeric RNA transcripts, each comprising a different, unique
subject RNA preferably encoding a particular gene product, and a
common UtRNA. These expression vectors are then introduced into
target cells or organisms, which are capable of transcribing the
chimeric RNA transcripts and translating the encoded gene products,
thereby creating a plurality of transfected target cells or
organisms, each collection of target cells or organism transfected
with the same expression vector expressing the same chimeric RNA
transcript and encoded gene product. In a preferred embodiment the
transfected target cells or organisms are arranged in an
addressable array, with cells or organisms transfected with a
single expression vector exclusively occupying a specific address
within the array. A UiRNA that is capable of inducing RNAi by
targeting the common UtRNA shared by all expression vectors and
chimeric RNA transcripts, in all transfected target cells or
organisms can then be introduced into these transfected target
cells or organisms to simultaneously reduce expression of all
recombinantly expressed gene products. As mentioned above, the
means by which the UiRNA is introduced into the transfected target
cells include introduction by way of a DNA that directs the in vivo
transcription of RNA, as well as by introduction of in vitro
synthesized RNA. Also, as mentioned above, the RNA transcribed or
synthesized can be a double-stranded siRNA-like UiRNA, or can be a
shRNA that is processed by cellular RNases to form the UiRNA.
[0018] The methods of the present invention also provide a means of
investigating the effects of altered levels of gene product
expression for a plurality of gene products by providing a
plurality of expression vectors that are introduced into a cell and
direct the expression of a chimeric RNA transcripts, each encoding
a particular gene product and bearing a common UtRNA. These
expression cassettes are introduced into target cells that are
capable of transcribing and translating the chimeric RNA
transcripts; thereby creating a plurality of transfected target
cells that overexpress the gene product cloned into the expression
cassette (also referred to as the gene product under study). At
some point in time relative to the introduction of the expression
cassette, UiRNA is introduced into the transfected target cells.
The introduced UiRNA, which corresponds in sequence to the UtRNA,
induces RNAi and promotes the degradation of the chimeric RNA
transcripts bearing the UtRNA. The net result is a reduction in the
expression of the particular gene product expressed from the
chimeric RNA transcript produced in that cell. Differences in the
transfected target cells before and after introduction of the UiRNA
are detected and measured, and are preferably correlated with
differences in the levels of expression of the gene product. Using
such an approach the effects of altered gene expression are
observed, and the function of the gene product whose expression
levels are manipulated is revealed.
[0019] Importantly, the methods of the present invention can be
employed to manipulate levels of expression of gene products in
cells, tissues, or organisms transfected with the expression
cassettes of the present invention. In particular, the type of RNA
introduced to induce RNAi, the amount of RNA introduced (dosage),
the means by which it its introduced (route and method of
introduction--e.g., lipofection, electroporation or synthesis in
vivo) can be adjusted to produce the quantitative and temporal
manipulation of gene product expression desired.
[0020] The methods of the present invention can be used with any
type of cell that (1) can be transfected with the expression
cassettes of the present invention, (2) will direct the production
of the chimeric RNA transcripts of the present invention, (3) to
which UiRNA can be introduced, and (4) that exhibits RNAi.
Importantly, the methods of the present invention can be used in a
variety of cell types or cell lines, and different cell types or
cell lines can be chosen to create different experimental
scenarios. In particular, cell lines that show distinctly different
endogenous levels of expression of the gene product under study, or
no expression of the gene product under study, can be chosen to
augment the methods of the present invention for studying gene
product function. Additionally, the methods of the present
invention can be employed in cell types, cell lines, tissues or
organisms that exhibit transitive RNAi, with very different effect.
These different scenarios are presented in more detail below.
[0021] The present invention further provides kits that can be used
to either target a plurality of recombinantly expressed gene
products for RNA interference, or to determine the effects of
altered levels of gene product expression. These kits can comprise
one or more vectors, including expression vectors having an
expression cassette comprising a multiple cloning site and a UtRNA,
wherein the expression cassette is capable of directing the
expression of a recombinant transcript comprising the UtRNA and any
nucleotide sequence inserted into the multiple cloning site (a
subject RNA). The kits further comprise either interfering RNAs
that effectively induce the RNAi of expression of the recombinantly
expressed gene product, or transcription vectors that direct the in
vivo transcription of such RNAs. These RNAs, which are designed to
induce RNAi by specifically targeting the UtRNA contained in the
recombinant transcripts, correspond in sequence to the UtRNA.
[0022] In one set of embodiments, the present invention provides
arrays of cultured cells, tissues, or organisms wherein the cells,
tissues, or organisms at specific addresses in the array have been
transfected with expression vectors comprising a chimeric
expression cassette having a nucleotide sequence encoding a
particular gene product, and a common UtRNA. The chimeric
expression cassettes in these transfected and arrayed cultures of
cells, tissues or organisms are capable of directing the expression
of chimeric RNA transcripts encoding different gene products, but
bearing the same UtRNA. Consequently, the expression of all gene
products in all transfected and arrayed cultures of cells or
organisms can be subjected to a reduction of expression by inducing
RNAi with a common UiRNA, that is administered to the cells or
organisms. Such arrays of transfected cultured cells should be made
up of at least 2, 3, 4, 5, preferably 6, 8 or 12, and more
preferably 16, 24, 32, 36, 40, 48, 56, 60, 64, 72, 80, 84, 88, 96
or more groups of cells or organisms transfected with different
chimeric expression vectors, all capable of directing the
expression of chimeric RNA transcripts encoding different gene
products, but bearing a common UtRNA. Such arrays of transfected
cultured cells, tissues, or organisms can be arranged in strips of
2, 3, 4, 6, 8, 12, or more culture tubes or vessels, or in 96-well
plates, or the likes. Cells in such arrays can be grown in
suspension, or as a monolayer on a substrate. Alternatively,
microarrays of transfected cells can be made in a monolayer of
cells attached to a common substrate as described by Sabatini in
U.S. Pat. No. 6,544,790, which is incorporated by reference herein
in its entirety.
[0023] In another set of embodiments, the present invention further
provides methods by which the involvement and/or role of a
plurality of gene products in pathogenesis, genetic disorders, or
infectious diseases can be assessed. For these embodiments, the
nucleotide sequences encoding gene products suspected or known to
be associated with or involved in a particular infectious disease
or genetic disorder are inserted into the expression cassettes of
the present invention. These expression cassettes, which may be
further incorporated into expression vectors, are introduced into
cells of an appropriate cell type or line to produce transfected
target cells or tissue, or into whole organisms to produce
transfected organisms. Once inside the cells or organisms, the
expression cassettes direct the production of chimeric RNA
transcripts that encode the different suspect gene products, but
bear a common UtRNA. The levels of expression of the encoded gene
products can be further manipulated in the transfected target cells
or organisms by the introduction of RNA(s) corresponding in
sequence to the UtRNA that induce RNAi by targeting the UtRNA
(UiRNAs). The transfected target cells or organisms can then be
examined in the presence and absence of such UiRNAs, to determine
whether the gene product whose expression level is being
manipulated by RNAi, does indeed play a role in pathogenesis,
genetic disorders, or infectious diseases. For example, the
transfected target cells or organisms can be exposed to an
infectious agent in the absence of UiRNA (conditions under which
expression of the gene product encoded in the chimeric RNA
transcripts will be enhanced), or in the presence of UiRNA
(conditions under which expression of the gene product encoded in
the chimeric RNA transcripts will be silenced or reduced). If the
gene product under study plays a role in the infectious cycle of
the infectious agent, differences in the health of the transfected
target cells or organisms will likely be observed between identical
cultures of the transfected target cells or organisms maintained
under the two different treatment regimes (i.e., in the presence or
absence of UiRNA).
[0024] In still another set of embodiments, the present invention
also provides methods of treating disease by manipulating the
levels of expression of a particular gene product. Such methods may
be applied to human cells, tissues or patients, or may be applied
to non-human cells, tissues or organisms. For humans, the method
comprises the steps of administering to a person in need of such
treatment a chimeric expression cassette comprising a nucleotide
sequence that directs the expression of a chimeric RNA transcript
encoding a particular gene product and a UtRNA, and introducing
into the person an RNA that induces RNAi of expression of the
encoded gene product by targeting the UtRNA in the recombinant
transcript. As above, the step of introducing the siRNA can be by
way of introducing a DNA that directs the in vivo transcription of
an RNA that induces RNAi, or alternatively, can be by way of
introducing an RNA that has been synthesized in vitro and induces
RNAi in vivo. The RNA introduced can be a double-stranded siRNA, or
a single-stranded hairpin RNA that is processed into an siRNA by
RNases. RNAs that are synthesized in vitro can be synthesized
either enzymatically or chemically. The RNA can include modified
nucleotides of any type, as well as other chemical modifications
that impart characteristics such as improved stability, resistance
to nucleases, greater efficacy, etc.
[0025] The diseases being treated in human can be genetic disorders
or infectious diseases. The infectious diseases can be diseases
caused by any type of pathogen, including viruses, bacteria, fungi,
parasitic protozoa, nematodes, etc. Viral diseases that can be
treated include diseases caused by human immunodeficiency virus
(HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), human
herpesvirus 1 (HSV1), human herpesvirus 2 (HSV2), human influenza A
(HIA), and the like. Also, the gene products whose expression
levels are being manipulated can be mammalian gene products, human
gene products or pathogen gene products, including viral gene
products.
[0026] Advantageously, in cells or organisms that naturally
exhibit, or are made to exhibit, transitive RNAi, the methods of
the present invention further provide a means to reduce the
expression of recombinantly expressed gene products, as well as
endogenous gene products. In such organisms, or the cells from such
organisms, RNAi induced gene silencing caused by UiRNAs that target
UtRNAs in expressed chimeric RNA transcripts would likely transit
or propagate to transcripts bearing sequences either identical to,
or highly similar to the sequence encoded in the chimeric
transcripts. Hence, in such cells or organisms the methods of the
present invention can be used to promote the silencing of
expression of any endogenous gene product without having to design
or administer gene-specific siRNAs. Further, multiple endogenous
gene products can potentially be silenced in such organisms or
cells using a single UiRNA that is targeted to the UtRNA in a
plurality of chimeric RNA transcripts that also bear the sequences
encoding the endogenous gene products to be silenced (subject
RNAs).
BRIEF DESCRIPTION OF THE DRAWINGS
[0027] FIG. 1 depicts five different exemplary configurations of
chimeric RNA transcripts that can be produced from five different
types of expression cassettes of the present invention. Each of the
five configurations includes a 5' UTR, 3' UTR, nucleotide sequence
that encodes the gene product whose expression is to be manipulated
(the subject RNA), and a universal target RNA (UtRNA). In the first
two examples the UtRNA is found in non-coding sequence, and the
last three examples the UtRNA encodes a peptide, preferably a
readily detectable peptide, and is cloned in-frame with the open
reading frame encoding a particular gene product;
[0028] FIG. 2 depicts how the methods of the present invention can
be used in an array-based format to target a plurality of gene
products for RNAi with a single type of UiRNA, thereby
simultaneously manipulating the expression levels of this plurality
of gene products;
[0029] FIG. 3 illustrates how a UiRNA is used to target a chimeric
RNA transcript for degradation in target cells expressing a
corresponding endogenous transcript, wherein the target cells do
not exhibit transitive RNAi;
[0030] FIG. 4 illustrates how a UiRNA is used to target a chimeric
RNA transcript for degradation in target cells that do not express
a corresponding endogenous transcript, and wherein the target cells
do not exhibit transitive RNAi; and
[0031] FIG. 5 illustrates how the methods of the present invention
can be used to manipulate gene expression in target cells that
express a chimeric RNA transcript, as well as a corresponding
endogenous transcript, and also exhibit transitive RNAi.
DETAILED DESCRIPTION OF THE INVENTION
1. Definitions
[0032] As used herein, the term "RNA interference," or "RNAi,"
refers to the process whereby sequence-specific,
post-transcriptional gene silencing is initiated by an RNA that is
homologous in sequence to the silenced gene. RNAi, which occurs in
a wide variety of living organism and their cells, from plants to
humans, has also been referred to as post-transcriptional gene
silencing (PTGS) and co-suppression in different biological
systems. The sequence-specific degradation of mRNA observed in
RNAi, is mediated by small (or short) interfering RNAs
(siRNAs).
[0033] As used herein, the term "transitive RNA interference,"
refers to the process whereby RNAi induced by an administered or
introduced siRNA (the primary siRNA) leads to the in vivo formation
of a population of secondary siRNAs, generally corresponding to
nucleotide sequences nearby, but distinct from, the nucleotide
sequence targeted by the primary siRNA. These secondary siRNAs
induce a secondary RNAi response in which transcripts bearing
nucleotide sequences corresponding to the secondary siRNAs are
targeted for endonucleolytic cleavage. The term "transitive RNAi"
refers to the ability of secondary siRNAs to "transit" the RNAi
gene-silencing phenomenon from the originally targeted transcript
to different transcripts bearing regions of nucleotide sequence
homologous to the sequences of the secondary siRNAs.
[0034] As used herein, the term "interfering RNA" means an RNA
molecule capable of directing the degradation of an RNA transcript
having a nucleotide sequence at least a portion of which is
substantially the same as that of the interfering RNA, through the
mechanism of RNA interference (RNAi). As known in the art,
interfering RNAs can be "small interfering RNAs," or siRNAs,
composed of two complementary single-stranded RNAs that form an
intermolecular duplex. Interfering RNAs can also be "short hairpin
RNAs," or shRNAs, composed of a single-stranded RNA with two
self-complementary regions that allow the RNA to fold back upon
itself and form a stem-loop structure with an intramolecular duplex
region and an unpaired loop region. Finally, in some circumstances
(See Martinez et al., Cell 110:563-574 (2002)), interfering RNAs
can be single-stranded antisense RNAs of 19 to 29 nucleotides that
are complementary to a target sequence.
[0035] The terms "small interfering RNA" (also sometimes referred
to as short interfering RNA) or "siRNA," as used herein, refer to
the mediators of RNAi-RNA molecules capable of directing
sequence-specific, post-transcriptional gene silencing of specific
genes with which they share nucleotide sequence identity or
similarity. Recent experiments have shown that the siRNAs that are
most effective in mammalian cells are duplexes composed or two
complementary 21 nucleotide single-stranded RNAs that anneal to
form a duplexed region of 19 basepairs and single-stranded
overhangs of 2 nucleotides at their 3' ends. In some organisms
(e.g., C. elegans, D. melanogaster and various plants) these siRNAs
can be created by the nucleolytic processing of longer dsRNAs. In
mammalian cells they apparently can also be produced from short
(i.e., less than 30 basepairs) hairpin RNAs, or shRNAs.
[0036] The term "small hairpin siRNA," "short hairpin siRNA," or
"shRNAs," as used herein, refers to siRNAs composed of a single
strand of RNA that possesses regions of self-complementarity that
cause the single strand to fold back upon itself and form a
hairpin-like structure with an intramolecular duplexed region
containing at least 19 basepairs. Importantly, because they are
single-stranded, shRNAs can be readily expressed from single
expression cassettes.
[0037] The term "knock down," as used herein, describes the
condition created by RNAi, wherein the expression of a particular
gene-product, or the cellular concentration of a particular RNA
transcript, is reduced or eliminated by the sequence-specific,
post-transcriptional gene silencing initiated by siRNAs that are
homologous in sequence to the gene encoding said gene product.
[0038] The term "subject RNA," as used herein, refers to an RNA
whose cellular concentration is to be altered, manipulated or
reduced, or knocked down, by the action of an interfering RNA
targeting the universal target RNA, but not the subject RNA.
[0039] As used herein, the term "chimeric RNA transcript" means an
RNA transcript comprising a subject RNA operably linked to a
universal target RNA to create a single RNA that does not naturally
occur in nature.
[0040] The term "operably linked," when used in the context of a
chimeric RNA transcript, means joined directly or indirectly such
that the universal target RNA facilitates the reduction in
concentration of at least the subject RNA when the chimeric RNA
transcript is subjected to RNA interference induced by a universal
interfering RNA.
[0041] The term "universal target RNA," or UtRNA, as used herein,
refers to a common RNA that is incorporated into a plurality of
chimeric RNA transcripts, and serves to impart upon the chimeric
RNA transcripts a susceptibility to degradation by RNA interference
promoted by a "universal interfering RNA" targeting the universal
target RNA.
[0042] The term "in vitro transcription," as used herein, describes
the process whereby a new (nascent) RNA molecule is synthesized,
outside of a living cell, from individual
ribonucleotides-triphosphates by an enzyme (usually RNA
polymerase), using a DNA molecule as a template to specify the
sequence of the nascent RNA.
[0043] As used herein, the term "transcription vector" refers to a
vector containing, at least, a promoter that directs transcription
by an RNA polymerase, a transcription template sequence, and a
transcription terminator sequence, such that an RNA transcript can
be synthesized from the transcription vector.
2. Overview and Embodiments
[0044] The present invention describes a novel method for
manipulating the expression of a plurality of gene products within
a cell or organism using a UiRNA that is designed to specifically
target a UtRNA. The methods of the present invention, which can be
employed in numerous alternative embodiments, can be used for a
variety of purposes. Specifically, the methods of the present
invention can be used to target a plurality of recombinantly
expressed gene products for RNAi using a single, common UiRNA. The
methods of the present invention can also be used to determine the
effects of altered levels of gene expression, preferably for a
plurality of genes, and preferably in arrayed collections of cells.
The methods of the present invention can also be used to identify
gene products that play important roles in pathogenesis, genetic
disorders, and infectious diseases.
[0045] The present invention also provides kits that can be used to
target a plurality of recombinantly expressed gene products for RNA
interference using a single, common UiRNA. The present invention
further provides for arrays of transfected cells, preferably
created through the use of transfection microarrays, in which a
single UiRNA can be used to induce RNAi of a plurality of gene
products, each expressed in a collection of cells at a specific
address within the array. The methods of the present invention,
when utilized in organisms or cells exhibiting transitive RNAi,
provide a method of reducing the expression of a plurality of
endogenous genes, using a UiRNA that is targeted to a UtRNA, when a
nucleotide sequence encoding the endogenous gene, or a homologue
thereof, is included along with a UtRNA in a single chimeric RNA
transcript. Consequently, in organisms or cells that either
naturally exhibit transitive RNAi, or are made to carry out
transitive RNAi, the methods of the present invention provide a
method for treating disease that involves reducing the cellular
concentration of gene products encoded by endogenous RNA
transcripts by first targeting a chimeric RNA transcript bearing a
UtRNA and encoding a gene product whose endogenous expression is
desired to be reduced, using UiRNA-induced RNAi to initially reduce
the expression of the recombinantly expressed gene product, and
allowing secondary siRNAs generated during that process to transit
and cause the RNAi-mediated degradation of endogenous transcripts
encoding the target gene product, and homologues thereof. These
various embodiments are described in detail below.
[0046] It should be stressed that the methods of the present
invention can be expected to have very different effects, and hence
different uses, in cells and organisms that naturally exhibit
transitive RNAi, or can be made to do so, as opposed to those that
do not. In the former--cells and organisms that naturally exhibit
transitive RNAi, or can be made to do so--the methods of the
present invention can be expected to result in a net reduction of
expression of the plurality of gene products encoded in the
plurality of expression vectors tested. This net reduction of
expression results from the production of secondary siRNAs, which
can transit to target homologous endogenous transcripts and promote
their endonucleolytic cleavage. In such cells and organisms, the
methods of the present invention can be expected to reduce the
expression of the gene products under study to levels below those
naturally occurring in untreated target cells. In contrast, in
cells or organisms that do not exhibit transitive RNAi, the methods
of the present invention can be expected to result in levels of
expression of the plurality of gene products encoded in the
plurality of expression vectors tested somewhere between those of
untransfected target cells (i.e., the natural background levels),
and cells transfected with the expression vectors of the present
invention (i.e., the overexpressed levels). In these cells and
organisms, the methods of the present invention can be used to
investigate the effects of overexpression of the plurality of gene
products encoded in the plurality of expression vectors tested,
followed by a partial reduction in their expression level. In such
cells and organisms the methods of the present invention can be
useful for investigating the disregulation of expression of the
plurality of gene products encoded in the plurality of expression
vectors tested.
[0047] The present invention provides a method for manipulating the
levels of expression of a plurality of gene products using a UiRNA
that is targeted to a UtRNA incorporated into chimeric RNA
transcripts expressed from expression cassettes or expression
vectors in target cells. These chimeric RNA transcripts, which can
encode any gene product, comprise a subject RNA and a UtRNA, and
the UtRNA can be incorporated into the chimeric RNA transcripts in
any location with respect to the subject RNA (FIG. 1). The method
overcomes the limitations faced in the prior art. First, the same
UtRNA is incorporated into a plurality of chimeric RNA transcripts,
a single type of UiRNA, which targets that that UtRNA, can be used
to reduce the expression of all gene products encoded by that
plurality of chimeric RNA transcripts. Second, the UtRNA targeted
by the UiRNA, and the UiRNA employed, can be selected and tested in
advance, in order to assure that (a) UiRNA-mediated, RNAi-induced,
gene silencing works effectively and without regard to the location
of the UtRNA in the chimeric RNA transcripts, or the identity of
the gene product coding sequence included within the chimeric RNA
transcripts, and (b) the UiRNA employed results in minimal, or
negligible off-target gene silencing. These advantages are
discussed in further detail below.
[0048] Currently, in order for researchers to use RNAi to
effectively silence the expression of specific heterologous
recombinant or endogenous gene products, they must design and test
specific siRNAs that target that the transcript encoding the
particular gene product whose levels of expression they wish to
reduce. Each gene to be silenced requires that a specific siRNA, or
set of siRNAs, be designed to promote RNAi-induced silencing, and
each siRNA designed must be tested for its efficacy. Since not all
sequences within transcripts encoding particular gene products are
efficiently targeted by corresponding siRNAs, researchers must
generally conduct preliminary experiments to empirically determine
which sequences, and their corresponding siRNAs, work best for
RNAi-mediated gene silencing (see Holen et al., Nucleic Acids Res.
30:1757-1766 (2002)).
[0049] Similarly, as described above, there is a growing body of
evidence that specific siRNAs selected to silence particular genes
may produce unwanted and unanticipated "off-target"
effects--altering the expression of untargeted RNA transcripts. In
fact, treatment of cells with siRNAs corresponding to different
sequences within the same targeted RNA transcript has been shown by
expression profiling to result in different, but reproducible,
off-target silencing effects. Apparently, at least some of these
off-target effects may be due to partial sequence homology between
the affected transcripts and either the sense or the antisense
strand of the siRNA employed, but some could not be explained by
sequence homology, leading the researchers to conclude that it may
be difficult to select an siRNA sequence that will be absolutely
specific for the target of interest (Jackson et al., Nature
Biotech. 21:635-637 (2003)). Since the UtRNA of the present
invention, and the UiRNA which targets it, can be selected and
tested in advance, such undesirable off-target effects can be
minimized. Furthermore, since the chimeric RNA transcripts of the
present invention that encode different gene products in the
subject RNA bear the same UtRNA, they can all be silenced by
introduction of the same UiRNA. And since Jackson and colleagues
have shown that the off-target silencing effects of specific siRNAs
are distinct and reproducible, use of the same UiRNA for the
induction of RNAi in different target cells bearing different
chimeric RNA transcripts, at least results in equivalent off-target
silencing effects in all target cells, thereby eliminating any
variability that might otherwise result from the introduction of
different, transcript-specific, siRNAs to different target
cells.
[0050] Certainly, incorporating a common UtRNA in a plurality of
chimeric RNA transcripts, and targeting those chimeric RNA
transcripts for RNAi-induced degradation through the introduction
of a single corresponding UiRNA, eliminates the need for designing
and testing different gene-specific siRNAs and may reduce or
eliminate the variability of silencing effects caused by
introduction of different gene-specific siRNAs. Further, a UtRNA
and its corresponding UiRNA can be chosen and tested in advance to
ensure that (a) the expression of gene products encoded by
recombinant transcripts bearing a UtRNA are effectively silenced by
introduction of a corresponding UiRNA, and (b) the silencing
observed is specific. Additionally, and advantageously, a UtRNA
that functions effectively and specifically in one chimeric RNA
transcript, should function equally well in other chimeric RNA
transcripts encoding different gene products. Similarly, since
UtRNAs can be identified that have little or no similarity to any
endogenous nucleotide sequences, UiRNAs targeting these UtRNAs can
be expected to have little or no homology-related effect on
endogenous gene expression--unless the cell or organism in which
the UtRNA/UiRNA system is employed exhibits transitive RNAi. In
which case, UiRNA-induced silencing of expression of a chimeric
transcript having a subject RNA operably linked to a UtRNA may be
expected to "transit" to endogenous sequences, leading to their
silencing as well. In such cells or organisms, use of pre-selected
UiRNA targeted to a UtRNA in a chimeric RNA transcript should lead
to the silencing of corresponding endogenous genes or gene
families.
[0051] Since a single UtRNA can be incorporated into any number of
chimeric RNA transcripts, and that UtRNA can be targeted by a
single type of UiRNA, another significant advantage of the present
invention is that the methods disclosed can be used to effectively
manipulate the expression of a plurality of gene products. Such
manipulation of expression of a plurality of gene products may be
done either simultaneously or nonsimultaneously. Consequently, the
methods of the present invention can be used to determine the
effects of altered levels of expression of a plurality of gene
products in a plurality of cells, or cell clusters or cultures, or
organisms transfected with expression cassettes directing the
expression of chimeric RNA transcripts bearing a common UtRNA, but
encoding different gene products. Specifically, groups of
transfected cells or organisms can be prepared, each group
transfected with a different expression cassette that directs the
expression of a specific chimeric RNA transcript encoding a unique
gene product in a subject RNA, but bearing a common UtRNA. These
groups of cells or organisms, each of which directs the
overexpression of the particular gene product encoded by their
expression cassette, can be treated with the same UiRNA to reduce
the expression of these particular gene products (FIG. 2).
Consequently, the method of the present invention provide a means
for determining the effects of altered levels of expression of a
plurality of gene products, using a single type of siRNA to promote
RNAi-induced silencing of expression of the heterologous gene
products encoded in the various chimeric RNA transcripts. Such
groups of transfected cells or organisms can be cultured, split
into a pair of cultures and one member of the pair can be treated
with UiRNA. Cells or organisms from the treated and untreated
paired cultures can then be compared to determine the effects of
altered levels of expression of the particular gene product encoded
by the expression cassette carried by those cells or organisms. The
comparison of treated and untreated paired cultures can be by any
means known to the art. Comparisons could, for example, involve
comparing growth rates, comparing cellular morphologies, comparing
the expression of specific cellular markers, or comparing the
performance or behavior of the cells or organisms in specific
diagnostic assays.
[0052] In preferred embodiments of the present invention the UtRNA
employed can be designed to encode a readily detectable peptide,
such as an epitope tag, fluorescent peptide, enzymatic tag, etc.,
such that, when cloned in-frame with a nucleotide sequence encoding
a gene product whose expression is to be manipulated, the UtRNA
directs the addition of the detectable peptide to the expressed
gene product. The UtRNA encoding the detectable peptide can be
added to either end of the sequence encoding the gene product to be
manipulated so that the detectable peptide tag is added to one end
or the other of the native gene product (FIG. 1). Alternatively,
the UtRNA can be cloned within the sequence encoding the gene
product to be manipulated, so that the detectable peptide tag is
found imbedded within the natural polypeptide sequence of the gene
product (FIG. 1). Preferably, and regardless of the location chosen
for the detectable peptide tag encoded by the UtRNA and added to
the polypeptide sequence of the gene product whose expression is to
be manipulated, the detectable peptide tag added to the expressed
gene product facilitates the ready detection, quantitation, and
perhaps localization of the resulting expressed fusion protein.
Hence, the detectable peptide tag can be exploited by researchers
to track or follow not only the levels of expression of the
recombinantly expressed fusion protein directed by the expression
cassette in which it is encoded, but also can be used to track or
follow the effects of treatment of such cells with corresponding
UiRNAs, or control siRNAs. In other words, the detectable peptide
tag present on a recombinantly expressed fusion protein allows
researchers to readily assess whether the desired gene is being
overexpressed at the protein level in transfected target cells
before the introduction of UiRNA, and whether the expression of the
protein is diminished or silenced following the introduction of, or
treatment with, siRNAs.
[0053] On the other hand, the UtRNA need not necessarily be
designed to encode a detectable peptide, and need not necessarily
be cloned within, or directly adjacent to the coding region
encoding the gene product whose expression is to be manipulated.
The expression cassettes of the present invention may be designed
and assembled such that the UtRNA ends up in the 5' untranslated
region, or in the 3' untranslated region of the recombinant
transcript encoding a gene whose expression is to be manipulated
(FIG. 1). In essence, the location of UtRNA in the chimeric RNA
transcript is a matter of choice, so long as the UtRNA allows for
the effective targeting of the chimeric RNA transcript for
RNAi-induced degradation of the subject RNA when cells (or
organisms) are treated with UiRNAs of corresponding sequence.
[0054] Importantly, cell types or cell lines vary with respect to
their basal levels of expression of a particular gene product or
family of gene products. Clearly, the type or line of cells chosen
for practicing the methods of the present invention will have a
profound effect on the results one will attain using the methods of
the present invention, since different cell types or cell lines
exhibiting different basal levels of endogenous expression of
various gene products can be employed to practice the methods of
the present invention. Generally speaking, and for the purpose of
practicing the methods of the present invention, all cell types can
be grouped into one of two categories, based on whether the cells
of that cell type or line express a particular gene product or not.
All cell types can be further divided into one of two categories
based on whether they exhibit transitive RNAi or not. As described
above, transitive RNAi refers to the process whereby RNAi induced
by an administered siRNA (the primary siRNA) leads to the secondary
silencing of non-targeted transcripts, such as transcripts of
homologous sequence. As will be seen, the methods of the present
invention can be expected to have significantly different net
effects with respect to the manipulation of expression of a
particular gene product depending upon in which of the resulting
four categories the cell type or line falls (i.e., (a) expressing a
particular gene product from an endogenous gene, and not exhibiting
transitive RNAi, (b) not expressing a particular gene product from
an endogenous gene, and not exhibiting transitive RNAi, (c)
expressing a particular gene product from an endogenous gene, and
exhibiting transitive RNAi, and (d) not expressing a particular
gene product from an endogenous gene, and exhibiting transitive
RNAi). While not wishing to be bound by any theory, the methods of
the present invention are particularly useful in cells and
organisms that either naturally exhibit transitive RNAi, or are
otherwise made to exhibit transitive RNAi. These four categories
will be discussed separately below.
[0055] In the first category (FIG. 3), before transfection with an
expression vector of the present invention, the cell type or cell
line expresses a particular gene product (protein P.sub.E) from an
endogenous gene, but the cell does not exhibit transitive RNAi.
Following transfection with an expression vector of the present
invention, the transfected cells of the cell type or cell line
express the gene product from both the endogenous gene (protein
P.sub.E), and from the chimeric RNA transcripts of the present
invention (protein P.sub.R*). Following introduction of the UiRNA,
which targets the UtRNA of the chimeric RNA transcript, expression
of the gene product from the chimeric RNA transcripts of the
present invention (protein P.sub.R*) is silenced, but expression of
the gene product from the endogenous gene (protein P.sub.E)
continues. In this category, following the introduction of the
UiRNA, the levels of expression of the gene product under study are
not likely to drop below the initial level resulting from basal
expression from the endogenous gene.
[0056] In the second category (FIG. 4), before transfection with an
expression vector of the present invention, the cell type or cell
line does not express a particular gene product (protein P.sub.E)
from an endogenous gene, and the cell does not exhibit transitive
RNAi. Following transfection with an expression vector of the
present invention, the transfected cells of the cell type or cell
line express the particular gene product from the chimeric RNA
transcripts of the present invention (protein P.sub.R*). Following
introduction of the UiRNA, which targets the UtRNA of the chimeric
RNA transcript, expression of the gene product from the chimeric
RNA transcripts of the present invention (protein P.sub.R*) is
silenced. In this category, following the introduction of the
UiRNA, the levels of expression of the gene product under study
will generally drop significantly below the maximum levels of
expression directed by the transgene, but the amount by which the
expression level is reduced will depend upon numerous factors.
[0057] In the third category (FIG. 5), before transfection with an
expression vector of the present invention, the cell type or cell
line expresses a particular gene product (protein P.sub.E) from an
endogenous gene, and the cell exhibits transitive RNAi. Following
transfection with an expression vector of the present invention,
the transfected cells of the cell type or cell line express the
gene product from both the endogenous gene (protein P.sub.E), and
from the chimeric RNA transcripts of the present invention (protein
P.sub.R*). Following introduction of the UiRNA, which targets the
UtRNA of the chimeric RNA transcript, expression of the gene
product from the chimeric RNA transcripts of the present invention
(protein P.sub.R*) is silenced, and secondary siRNAs generated
during the primary RNAi response server to silence expression of
the gene product from the endogenous gene. In this category,
following the introduction of the UiRNA, the levels of expression
of the gene product under study will generally drop significantly
below the maximum levels of expression seen following transfection
of the transgene, and likely will drop below the initial levels
observed before the transfection of the transgene. How much below
initial levels gene product expression will drop depends upon how
effectively the silencing signal "transits" along the chimeric RNA
transcript and to corresponding endogenous transcripts to induce a
secondary RNAi response. Importantly, if the silencing signal
transits efficiently to endogenous transcripts, and if the gene
product under study is a member of a gene family, the secondary
RNAi response may also lead to the silencing of expression of
paralogous genes.
[0058] In the fourth category (not depicted), before transfection
with an expression vector of the present invention, the cell type
or cell line does not express a particular gene product (protein
P.sub.E) from an endogenous gene, but the cell does exhibit
transitive RNAi. Following transfection with an expression vector
of the present invention, the transfected cells of the cell type or
cell line express the particular gene product from the chimeric RNA
transcripts of the present invention (protein P.sub.R*). Following
introduction of the UiRNA, which targets the UtRNA of the chimeric
RNA transcript, expression of the gene product from the chimeric
RNA transcripts of the present invention (protein P.sub.R*) is
silenced. In this category, following the introduction of the
UiRNA, the levels of expression of the gene product under study
will generally drop significantly below the maximum levels of
expression directed by the transgene, but the amount by which the
expression level is reduced will depend upon numerous factors. As
above, if the silencing signal can transit efficiently to
endogenous transcripts, and if the gene product under study is a
member of a gene family--other members of which are expressed in
this cell type or line--then a secondary RNAi response may lead to
the silencing of expression of paralogous genes.
[0059] Cells that naturally exhibit transitive RNAi include, but
are not limited to the cells of C. elegans and plants. Other cells
may be induced or enabled to exhibit transitive RNAi by, e.g.,
introducing into the cells exogenous genes encoding the machinery
required for transitive RNAi. The expected results of methods of
the present invention as described above for cells naturally
exhibiting transitive RNAi are also expected to be obtained in
cells that are made to exhibit transitive. The results expected
from practicing the methods in such cell types (i.e., cells that do
not normally exhibit transitive RNAi, but are made to do so) are
identical to those described above for the third and fourth
categories.
[0060] In another set of embodiments, the methods of the present
invention provide kits for targeting a plurality of gene products
for RNAi using a single UiRNA targeted to a common UtRNA. The
methods of the present invention further provide kits for
determining the effects of altered levels of expression of a
plurality of gene products, or for assessing the involvement of a
particular gene product, amongst a plurality of gene products, in
pathogenicity, genetic disorders, and infectious diseases.
[0061] Typically, a kit should contain, in a carrier or
compartmentalized container, reagents useful in any of the
above-described embodiments of the invention. The carrier can be a
container or support, in the form of, e.g., bag, box, tube, rack,
and is optionally compartmentalized. The carrier may define an
enclosed confinement for safety purposes during shipment and
storage. Preferably, instructions for using a kit, and/or reagents
contained therein, are also included in the kit.
[0062] In one set of kit embodiments, the kits of the present
invention comprise one or more expression vectors that each
comprise an expression cassette having a multiple cloning site and
associated UtRNA, and an RNA that effectively directs RNAi of the
recombinantly expressed gene products by targeting the UtRNA in
chimeric RNA transcripts expressed from these expression cassettes.
Using such kits, the nucleotide sequence encoding a particular gene
product is conveniently cloned within the multiple cloning site of
the expression vector, such that the resulting assembled vector
directs the expression of a chimeric RNA transcript that comprises
a nucleotide sequence encoding a particular gene product (the
subject RNA) and the UtRNA. The RNA that is provided in the kits to
direct the RNAi of the recombinantly expressed gene products by
targeting the UtRNA, can be of any configuration that effectively
directs RNAi by targeting the UtRNA, however, in a preferred
embodiment the RNA is a single-stranded shRNA. In an alternative
preferred embodiment the RNA is a double-stranded siRNA.
[0063] In another set of kit embodiments, the kits of the present
invention comprise one or more expression vectors, as described
above, plus a transcription vector that directs the in vivo
transcription of an RNA that effectively directs the RNAi of
expression of gene products by targeting the UtRNA borne by the
chimeric RNA transcripts encoding the gene product whose expression
is to be reduced. In a preferred embodiment this RNA is a
single-stranded shRNA. In an alternative preferred embodiment, this
RNA is a double-stranded siRNA.
[0064] Further provided by the methods of the present invention are
gene product panel test kits designed to determine the effects of
altered levels of expression of a plurality of gene products. In
such kits a plurality of expression vectors, such as those
described above, are provided, but these vectors are provided each
with a different nucleotide sequence encoding a specific gene
product inserted into it, such that the vector directs the
transcription of a chimeric RNA transcript encoding a specific gene
product (the subject RNA) and bearing a common UtRNA. Also provided
in these gene product panel test kits would be either RNA that
targets the UtRNA and induces RNAi, or a transcription vector that
directs the expression of such an RNA. Preferably the RNA is either
a small single-stranded hairpin RNA, or a double-stranded siRNA.
Advantageously, these gene product panel kits include at least two
expression vectors that direct the expression of different gene
products, but the expression of all gene products encoded in the
supplied vectors can be reduced by introducing an RNA designed to
promote RNAi by targeting the UtRNA in the chimeric RNA transcripts
encoded in the supplied vectors (i.e., a UiRNA). Preferably these
gene product panel test kits contain at least 2, 3, 4, 6, 8, 12,
16, 24, 32, 36, 40, 48, 56, 60, 64, 72, 80, 84, 88, 96 or 160, 240,
360, 400, 480, 560, 600, 1000 or more such expression vectors, each
capable of directing the expression of a different gene product,
and directing the production of a chimeric RNA transcript
comprising a UtRNA and the nucleotide sequence encoding a specific
gene product (the subject RNA).
[0065] Beneficially, the expression vectors of these gene product
panel test kits can encode different human gene products that are
related in sequence or function (i.e., drug metabolizing enzymes,
such as mixed function oxidases, cytochrome P450 enzymes, and the
like), or are involved in a single metabolic pathway, or represent
a collection of interacting proteins that are associated with a
particular genetic disorder or infectious disease.
[0066] Alternatively, the expression vectors of these gene product
panel test kits may encode different gene products from a human
pathogen (e.g., viral genes from a human viral pathogen, or
virulence factor genes from a human parasite), or the expression
vectors may encode gene products from a human pathogen that are
required for infection of, or maintenance within, a non-human
species that serves as a vector or reservoir for the disease (e.g.,
transmission factor genes of arboviruses or parasitic protozoa such
as Plasmodium falciparum). Also, the expression vectors of these
gene product panel test kits may encode different gene products
from non-human species that serve as vectors for transmission of
infectious diseases (e.g., genes known or suspected to be required
for infection of Aedes aegypti mosquitoes by West Nile virus).
Further, the expression vectors included in a gene product panel
test kit may be designed for producing the chimeric RNA transcripts
of the present invention in human cells, or in the cells of
non-human species that serve as vectors for transmission of
infectious diseases.
[0067] Alternatively, the expression vectors included in a gene
product panel test kit may be designed for producing the chimeric
RNA transcripts of the present invention in plant cells.
Innumerable such gene product panel test kits utilizing the methods
of the present invention can be envisioned by skilled artisans
appraised of the present invention, and the examples provided above
are not meant to limit the design or application of such kits.
[0068] In yet another set of embodiments, the methods of the
present invention provide for arrays designed to utilize RNAi to
either simultaneously manipulate levels of expression of a
plurality of gene products, or simultaneously determine the effects
of altered levels of expression of a plurality of gene products all
by using a single siRNA. For these embodiments, the methods of the
present invention provide for a transfection array of DNA
expression vectors, where the expression vectors at different
addresses within the array are capable of directing the production
of different chimeric RNA transcripts that have different subject
RNAs to be degraded, but bear a common UtRNA. The methods of the
present invention further provide for arrays of transfected cells,
wherein collections of cells at specific addresses within the array
are transfected with a particular DNA expression vector, and this
vector directs the production of a chimeric RNA transcript that
encodes a particular gene product but bears a common UtRNA. In this
manner, arrays of cells showing altered levels of expression of a
plurality of particular gene products are formed, but a single
siRNA can be used to induce RNAi and thereby diminish expression of
all gene products encoded by the chimeric RNA transcripts, by
introducing into the cells a UiRNA, which corresponds to, and is
capable of targeting, the UtRNA common to all of the chimeric RNA
transcripts expressed within the cells of the array.
[0069] Such arrays can be microarrays of transfected cells or
macroarrays of cultures of transfected cells. Such arrays can also
be macroarrays of organisms expressing the chimeric RNA transcripts
of the present invention. Examples of the organisms include
nematodes and plants. Nematode and plant cells, tissues, or plant
seeds can also be used in the arrays. For the microarrays, the
reverse transfection methods described by Sabatini in U.S. Pat. No.
6,544,790, which is incorporated by reference herein in its
entirety, can be used to prepare either the transfection
microarrays of expression vectors, or the microarrays of reverse
transfected cells) of these embodiments.
[0070] Kits including one or more of the arrays of the present
invention and a UiRNA are also contemplated.
[0071] Using these embodiments of the present invention (i.e.,
microarrays of reverse transfected cells, or macroarrays of
transfected cells or organisms) the levels of expression of a
plurality of gene products may be simultaneously manipulated as
required. Initially, and in the absence of UiRNA, all gene products
encoded in the chimeric transcripts of the present invention should
be overexpressed to some degree. The degrees to which the gene
products are overexpressed can be influenced by any means know in
the art. For example, different constitutive promoters, exhibiting
particular levels of transcriptional activity, can be incorporated
into the expression cassettes of the present invention. Promoters
exhibiting high transcriptional activity should lead to higher
levels of initial overexpression. Alternatively, inducible or
derepressible promoters can be incorporated into the expression
cassettes of the present invention. Such promoters, which are well
known in the art, can be manipulated by addition of particular
inducing or repressing agents to the cell culture medium in order
to intentionally alter their levels of transcriptional activity.
Once appropriate levels of expression of the plurality of gene
products under study are achieved, the levels of expression of the
plurality of gene products can be conveniently and simultaneously
diminished by the introduction of a single type of siRNA (UiRNA).
Introduction of UiRNA corresponding in sequence to the UtRNA found
in all chimeric RNA transcripts encoding the gene products under
study, induces RNAi, and it's associated silencing (reduction) of
expression of all gene products being expressed from the chimeric
RNA transcripts of the present invention. The introduction of UiRNA
can be by any means, but the means chosen, as well as the amount
introduced, and the nature of the UiRNA and corresponding UtRNA,
will determine the amount and duration of silencing (reduced
expression) observed.
[0072] Whatever the means of introduction of UiRNA, the methods of
the present invention provide a means to "silence," or generally
diminish expression, all of the gene products expressed by the
cells of the array. This allows the cells clusters at specific
addresses in the array to be compared under conditions of increased
expression of a particular gene product (in the absence of a
UiRNA), and decreased expression of a particular gene product (in
the presence of UiRNA). Since the expression levels of the
plurality of gene products expressed within the cells of the array
can be manipulated simultaneously and conveniently by a uniform
treatment (i.e., the introduction of UiRNA), the methods of the
present invention are particularly useful for the high-throughput
analysis of gene function, in which large sets of DNAs are screened
to identify those DNAs encoding gene products that cause cellular
phenotypes of interest, or exhibit other properties of
interest.
[0073] Importantly, as described above, cell types or cell lines
vary with respect to their basal levels of expression of a
particular gene product or family of gene products. Clearly, the
type or line of cells chosen for practicing the methods of the
present invention will have a profound effect on the results
attained, since different cell types or cell lines exhibiting
different basal levels of endogenous expression of various gene
products can be employed to make the microarrays and macroarrays
just described. Generally speaking, and for the purpose of
practicing the methods of the present invention, all cell types can
be grouped into one of four categories, based on whether the cells
of that cell type or line express a particular gene product or not,
and whether they exhibit transitive RNAi or not. As described
above, the methods of the present invention can be expected to have
different net effects with respect to the manipulation of
expression of a particular gene product depending upon in which of
these four categories the cell type or cell line falls.
[0074] In another set of embodiments, the methods of the present
invention provide a means to reduce the expression of endogenous
genes in organisms or cells that either naturally exhibit
transitive RNAi, or are made to do so. In these embodiments, the
coding region of the endogenous gene whose expression is desired to
be reduced is cloned within an expression cassette that also
includes a UtRNA and the expression cassette is included in an
expression vector. The coding region is inserted into the
expression cassette so that the cassette directs the expression of
a chimeric RNA transcript, comprising the nucleotide sequence
encoding the gene product of interest (the subject RNA) and a
UtRNA, adjacent to the coding region. For example, if designed to
encode a peptide, the UtRNA can be cloned in-frame with the 3' end
of the coding region, so that the UtRNA directs the addition of a
peptide tag to the carboxyl-terminus of the gene product.
Alternatively, the UtRNA may be cloned just downstream of the stop
codon, in the 3' UTR. The resulting expression vector is then
transfected into cells exhibiting transitive RNAi. Once
transfected, these cells express the chimeric RNA transcript
bearing the UtRNA. When reduction of endogenous expression is
desired, a UiRNA corresponding in sequence to the UtRNA is
introduced into the cell. This UiRNA serves as a primary siRNA that
induces a primary RNAi response by targeting the UtRNA in the
chimeric RNA transcript. During the primary RNAi response,
secondary siRNAs are generated corresponding to sequences 5' of the
UtRNA and in the region encoding the endogenous gene product. These
secondary siRNAs promote RNAi-induced silencing of the sequences to
which they correspond; namely the coding region 5' to the UtRNA.
Because the sequences that these secondary siRNAs target are common
to transcripts from both recombinantly-expressed and
endogenously-expressed genes, a secondary RNAi response induced by
these secondary siRNAs leads to reduced expression of gene products
encoded by both recombinant and endogenous transcripts. Hence, the
methods of the present invention can be used in any cell or
organism exhibiting transitive RNAi, whether naturally exhibited or
otherwise induced, to reduce the expression of any gene product
from endogenous transcripts.
[0075] Advantageously, the methods of the present invention can
also be used to reduce the expression of highly similar or
homologous gene products. It is known from experiments conducted in
organisms and cells exhibiting transitive RNAi, that siRNAs
targeted to a particular member of a gene family can ultimately
induce silencing of other members of that same gene family. The
mechanism by which this transitive secondary silencing occurs is
thought to involve the generation of secondary siRNAs corresponding
to nucleotide sequences outside of the region of nucleotide
sequences in transcripts originally targeted by the primary (i.e.,
introduced) siRNAs. (In C. elegans, these secondary siRNAs
correspond to nucleotide sequences 5' of the nucleotide sequence
targeted by the primary siRNA, but in plants the secondary siRNAs
correspond to nucleotide sequences both 5' and 3' of the originally
nucleotide targeted sequence.) If these secondary siRNAs correspond
to sequences that are shared by gene family members, these
secondary siRNAs will also target these gene family members for
silencing during a secondary RNAi response. However, in order for
gene family members to be targeted by secondary siRNAs, they must
possess regions of sequence that are identical to, or very similar
to, regions of sequence adjacent to the sequence targeted by the
original primary siRNAs.
[0076] The advantages to using the methods of the present
invention, in the manner described above, to reduce expression of
endogenous genes in cells and organisms exhibiting transitive RNAi,
are at least two-fold. First, if a particular UtRNA is incorporated
into a plurality of chimeric RNA transcripts, a single type of
siRNA that targets that that UtRNA (a UiRNA) can be used to reduce
the expression of all gene products encoded in that plurality of
chimeric RNA transcripts. Second, the UtRNA targeted by the UiRNA,
and the UiRNA employed, can be selected and tested in advance, in
order to assure that UiRNA-mediated gene silencing works
effectively and without regard to the nature of the gene product
coding sequence included within the chimeric RNA transcripts.
[0077] Importantly, however, in order for these embodiments to take
advantage of the phenomenon of transitive RNAi to affect silencing
of homologous messages, the UtRNA must be situated adjacent to, and
preferably nearby, the nucleotide sequence encoding the gene
product whose expression is to be reduced or silenced.
Advantageously, the UtRNA can either be inserted into the 3'
untranslated region just 3' of the stop codon, or, if made to
encode a peptide, can be cloned in frame with the 3' end of the
coding region for the gene product such that the chimeric RNA
transcript produced from the expression cassette encodes a fusion
protein. In the latter case, it is preferable for the peptide
encoded by the UtRNA to be a peptide, which can be used for the
ready detection and quantitation of the expressed fusion
protein.
[0078] In still another set of embodiments, the methods of the
present invention provide a method of treating disease in organisms
or cells that naturally exhibit transitive RNAi (i.e., nematodes
and plants), or in organisms or cells that are made to perform
transitive RNAi. In these embodiments, an expression cassette
directing the expression of a chimeric RNA transcript, comprising a
nucleotide sequence encoding a disease-related protein (as the
subject RNA) and a UtRNA, is introduced into the cells, or organism
in need of treatment. The expression cassette introduced directs
the production of a chimeric RNA transcript, which bears the
subject RNA and the UtRNA. At some point in time when a reduction
in the level of expression of the disease-related protein is
desired, a UiRNA, which corresponds in sequence to the UtRNA, is
introduced into the cells or organism to promote a reduction of
expression of the recombinantly expressed gene-product through a
primary RNAi response. During the course of the primary RNAi
response secondary siRNAs are produced that will correspond to
sequences adjacent to, or just upstream (5') of the UtRNA. These
secondary siRNAs induce a secondary RNAi response that results in
the reduction of expression or silencing of both recombinantly
expressed and endogenously expressed gene product. The net
reduction of expression of both recombinantly expressed and
endogenously expressed gene product, desirably promotes an
improvement in the disease state.
[0079] In a final set of embodiments, the methods of the present
invention provide a method of treating an infectious disease caused
by a pathogenic organism that naturally exhibits transitive RNAi.
In these embodiments, transitive RNAi is used to silence, or
significantly reduce, expression of a critical gene product (e.g.,
a virulence factor) in the pathogenic organism. Examples of
pathogenic organisms exhibiting transitive RNAi include nematode
worms, which result in a variety of diseases in agricultural crops
and livestock, and possibly protozoa, such as trypanosomes, which
cause a variety of diseases (i.e., sleeping sickness) in humans and
domesticated animals.
3. Expression Cassettes
[0080] It will be apparent to skilled artisans that any molecular
genetic engineering methods or recombinant DNA technologies may be
used in the present invention for purposes of preparing the
expression cassettes and expression vectors of the present
invention. Generally, once prepared, a nucleic acid encoding an
expression cassette can be incorporated into an expression vector
or a delivery vector, which is introduced to a suitable target
cell.
[0081] The expression cassettes employed in the various embodiments
described above can be of any suitable construction, and can be
included in any appropriate delivery vector. Such delivery vectors
include plasmid DNA, viral DNA, and the like. The means by which
the expression cassette in its delivery or expression vector is
introduced into target cells or target organism can be
transfection, reverse transfection, virus induced transfection,
electroporation, direct introduction by biolystics (e.g., using a
"gene gun;" BioRad, Inc., Emeryville, Calif.), and the like. Other
methods that can be employed include methods widely known in the
art as the methods of gene therapy. Once delivered into a target
cell, or target organism the expression cassette may be maintained
on an autonomously replicating piece of DNA (e.g., an expression
vector), or may be integrated into the genome of the target cell or
target organism.
[0082] Typically, to assemble the expression cassettes and vectors
of the present invention a nucleic acid, preferably a DNA, encoding
a gene product under study is incorporated into a unique
restriction endonuclease cleavage site, or a multiple cloning site,
within a pre-existing "empty" expression cassette bearing a
UtRNA-encoding sequence to form a complete recombinant expression
cassette that is capable of directing the production of the
chimeric RNA transcripts of the present invention. These chimeric
RNA transcripts comprise a subject RNA, generally encoding a
specific gene product, and the UtRNA, which can be targeted by a
corresponding UiRNA, to induced the RNAi-mediated degradation of
the chimeric RNA transcript. Frequently such complete recombinant
expression cassettes reside within, or inserted into, expression
vectors designed for the expression of such chimeric RNA
transcripts, and recombinant proteins. Many types of vectors can be
used for the present invention to produce chimeric RNA transcripts
bearing UtRNAs. Methods for the construction of an expression
vector for purposes of this invention should be apparent to skilled
artisans apprised of the present invention. (See generally, Current
Protocols in Molecular Biology, Vol. 2, Ed. Ausubel, et al., Greene
Publish. Assoc. & Wiley Interscience, Ch. 13, 1988; Glover, DNA
Cloning, Vol. II, IRL Press, Wash., D.C., Ch. 3, 1986; Bitter, et
al., in Methods in Enzymology 153:516-544 (1987); The Molecular
Biology of the Yeast Saccharomyces, Eds. Strathern et al., Cold
Spring Harbor Press, Vols. I and II, 1982; and Sambrook et al.,
Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press,
1989.)
4. Expression Vectors
[0083] Generally, the expression cassettes inserted or assembled
within the expression vectors have a promoter operably linked to a
DNA encoding the subject RNA that is to be manipulated, plus a
UtRNA. The promoter can be a native promoter, i.e., a promoter that
is responsible for the expression of that particular gene product
in cells, or it can be any other suitable promoter. Alternatively,
the expression cassette can be a chimera, i.e., having a
heterologous promoter that is not the native promoter responsible
for the expression of the gene product whose expression is to be
manipulated. Such heterologous promoters can even be from a
different species than the target cell or organism.
[0084] The expression vector may further include an origin of DNA
replication for the replication of the vectors in target cells.
Preferably, the expression vectors also include a replication
origin for the amplification of the vectors in, e.g., E. coli, and
selection marker(s) for selecting and maintaining only those target
cells harboring the expression vectors. Additionally, the
expression vectors preferably also contain inducible or
derepressible promoters, which function to control the
transcription of the chimeric RNA transcript from the DNA that
encodes it. Other regulatory sequences such as transcriptional
enhancer sequences and translation regulation sequences (e.g.,
Shine-Dalgarno sequence) can also be operably included in the
expression vectors. Transcription termination sequences, and
polyadenylation signal sequences, such as those from bovine growth
hormone, SV40, lacZ and AcMNPV polyhedral protein genes, may also
be operably linked to the DNA encoding the gene product whose
expression is to be manipulated.
[0085] As mentioned above, the UtRNA, which is also included in the
expression vector, may be situated in any of the five possible
locations, with respect to the subject RNA whose cellular
concentration is to be manipulated, or with respect to the coding
sequence of the gene product whose expression is to be manipulated,
as depicted in FIG. 1. In all cases the subject RNA is operably
linked to the UtRNA, such that the resulting chimeric RNA
transcript is subject to the RNAi-induced degradation when targeted
by an introduced UiRNA that corresponds in nucleotide sequence to
the nucleotide sequence of the UtRNA. If the particular embodiment
of the invention to be practiced exploits transitive RNAi to induce
the silencing of endogenous or homologous transcripts, and the
transitive RNAi takes place within a nematode, or nematode cell,
the coding sequence is preferably placed 5' of the UtRNA, in one of
two possible configurations. In the first of these two possible
configurations, the UtRNA, which is situated adjacent to the coding
region, is designed to encode a peptide sequence, and is placed in
frame with the 3' end of the coding sequence. In the second, the
UtRNA is placed in the 3' untranslated region, just downstream (or
3') of the stop codon. If the particular embodiment of the
invention to be practiced exploits transitive RNAi to induce the
silencing of endogenous or homologous transcripts, and the
transitive RNAi takes place within a plant, or plant cell, the
UtRNA can be placed in any location within the chimeric RNA
transcript, as long as it is operably linked to the subject
RNA.
[0086] In a preferred embodiment the UtRNA encodes a detectable
peptide, and is operably linked to the subject RNA by being placed
in frame with the 3' end of the coding sequence, such that the
expressed chimeric RNA transcript ultimately results in the
translation of a fusion protein with a carboxyl-terminal detectable
peptide tag.
5. Detectable Peptide Tags
[0087] As mentioned above, the UtRNA can encode an detectable
peptide tag that facilitates detection of an expressed fusion
protein bearing that tag. The tag may be an epitope tag that is
useful for immunodetection, quantitation, and possibly the
purification of the gene product under study. Such a UtRNA can be
operably linked to the DNA encoding the gene product whose
expression is to be manipulated such that a fusion protein bearing
the epitope tag is expressed. Examples of useful epitope tags
include, but are not limited to, influenza virus hemagglutinin
(HA), Simian Virus 5 (V5), polyhistidine (His6), c-myc, FLAG.TM.,
and the like. Specific antibodies immunoreactive with these epitope
tags, and many others, are commercially available. Additionally,
proteins expressed as fusions with polyhistidine tags can be easily
detected and/or purified with, e.g., Ni.sup.2+ affinity
columns.
[0088] If the UtRNA of the present invention is designed to encode
an epitope tag and is cloned in frame with the nucleotide sequence
encoding the gene product whose level of expression is to be
manipulated, the resulting fusion protein can be readily detected
by Western blotting. Also, the addition of an epitope tag allows
the expression level or concentration of the resulting fusion
protein to be determined in a sample, such as a cell lysate,
without the need for separation, isolation or purification. For
this purpose, it is preferred that an antibody selectively
immunoreactive with the epitope tag is used in an immunoassay. For
example, immunocytochemical methods can be used. Other well known
antibody-based techniques can also be used including, e.g.,
enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA),
immunoradiometric assays (IRMA), fluorescent immunoassays, protein
A immunoassays, and immunoenzymatic assays (IEMA). See e.g., U.S.
Pat. Nos. 4,376,110 and 4,486,530, both of which are incorporated
herein by reference. These antibody-based techniques are widely
known in the art and are described readily available references,
such as Using Antibodies: A Laboratory Manual (Harlow, Cold Spring
Harbor Press (1999)).
[0089] Alternatively, the UtRNA can encode any other type of
detectable peptide, including, but not limited to, fluorescent
peptides, or peptides exhibiting enzymatic activity. For example,
the UtRNA can encode enhanced green fluorescent protein, or any
other variety of fluorescent protein. Preferably, such fluorescent
peptides allow for the ready detection of expression of fusion
proteins bearing them, and even more preferably, they allow for the
quantitation of such fusion proteins. Examples of such fluorescent
peptides are widely known in the art, and protocols for their
detection and quantitation are available from a variety of
sources.
[0090] Examples of peptides exhibiting enzymatic activity are also
widely known in the art. Such peptides include, but are not limited
to, alkaline phosphatase, horseradish peroxidase, and
.beta.-galactosidase, which allow for the ready detection and
quantitation of fusion proteins bearing them using specific
enzymatic assays. Examples of such peptides exhibiting enzymatic
activity are widely known in the art, and protocols for their
detection and quantitation are available from a variety of
sources.
6. Additional Features
[0091] The expression vectors or the present invention may also
contain components that direct the recombinantly expressed gene
product or fusion protein to the surface of the cell, to a
particular intracellular compartment, or to be secreted, as
required. Signal peptides, nuclear localization sequences,
endoplasmic reticulum retention signals, mitochondrial localization
sequences, myristoylation signals, palmitoylation signals, and
transmembrane sequences are examples of optional components that
can determine the destination of expressed gene products. When it
is desirable to manipulate the expression of two or more gene
products in a single host cell by RNAi, two expression cassettes
directing the expression of two different chimeric RNA transcripts,
each encoding a single gene product, in a distinct subject RNA that
is operably linked to a UtRNA, may be incorporated into a single
vector. Alternatively, the two expression cassettes may reside
within two distinct expression vectors, both of which are
introduced into a single target cell. Advantageously, in either
scenario, the same UtRNA may be included in both expression
cassettes so that the same UiRNA can be used to reduce their
expression. Alternatively, a different UtRNA can be incorporated
into each expression cassette so that the expression of the two
different gene products can be manipulated independently.
[0092] The expression vectors of the present invention can be
introduced into the target cells by any techniques known in the
art, e.g., by direct DNA transformation, microinjection,
electroporation, viral infection, lipofection, biolystics, and the
like. The expression of the gene products to be manipulated may be
transient or stable, inducible or derepressible. The expression
vectors can be maintained in target cells in an extrachromosomal
state, i.e., as self-replicating plasmids or viruses.
Alternatively, the expression vectors, or portions thereof, can be
integrated into chromosomes of the target cells by conventional
techniques such as site-specific recombination or selection of
stable cell lines. In stable cell lines, at least the expression
cassette portion of the expression vector is integrated into a
chromosome of the target cells.
[0093] The vector construct can be designed to be suitable for
expression in various target cells, including but not limited to
bacteria, yeast cells, plant cells, nematode cells, insect cells,
and mammalian and human cells. Methods for preparing expression
vectors designed for expression of gene products in different
target cells are well known in the art.
7. Introduction of UiRNA
[0094] A universal interfering RNA, or UiRNA, can be introduced
into the transfected target cells of the present invention either
exogenously, i.e., from outside the target cells, or endogenously,
from transcription cassettes that direct the transcription of
UiRNAs within the target cells. For exogenous introduction, the
UiRNAs of the present invention are synthesized in vitro and
introduced by transfection, lipofection, electroporation, or any
other appropriate means. Such in vitro synthesized UiRNAs may be
synthesized by chemical means, or by enzymatic means from the
appropriate precursors. In addition, these in vitro synthesized
UiRNAs may take different forms. They may be double-stranded RNA
duplexes consisting of two annealed strands of about 21 nucleotides
that form about 19 basepairs between them and have 3' overhangs of
two nucleotides (Elbashir et al., EMBO J. 20:6877-6888 (2001) &
Chiu and Rana, Molec. Cell 10:549-561 (2002)). Alternatively, these
in vitro synthesized UiRNAs may be single-stranded short hairpin
RNAs (Sui et al., Proc. Natl. Acad. Sci. U.S.A. 99:5515-5520
(2002); Yu et al., Proc. Natl. Acad. Sci. U.S.A. 99:6047-6052
(2002); and Paul et al., Nature Biotech. 20:505-508 (2002)).
[0095] For endogenous introduction, UiRNAs are transcribed within
the target cells of the present invention. Such UiRNAs can be of
any appropriate form, but are preferably transcribed as small
hairpin RNAs that are processed to for active UiRNAs by cellular
nucleases. Transcription cassettes directing the expression of
UiRNAs, like the expression cassettes directing the expression of
chimeric RNA transcripts, described above, can be incorporated into
a transcription vector or a delivery vector, which is introduced to
a suitable target cell.
[0096] The expression cassettes employed for the in vivo
transcription of UiRNA can be of any suitable construction, and can
be included in any appropriate delivery vector. Such delivery
vectors include plasmid DNA, viral DNA, and the like. The means by
which the UiRNA expression cassette in its delivery or expression
vector is introduced into target cells or target organism can be
transfection, reverse transfection, virus induced transfection,
electroporation, direct introduction by biolystics (e.g., using a
"gene gun;" BioRad, Inc., Emeryville, Calif.), and the like. Other
methods that can be employed include methods widely known in the
art as the methods of gene therapy. Once delivered into a target
cell, or target organism the UiRNA expression cassette may be
maintained on an autonomously replicating piece of DNA (e.g., an
expression vector), or may be integrated into the genome of the
target cell or target organism.
[0097] Typically, to assemble the UiRNA expression cassettes and
vectors of the present invention a nucleic acid encoding the UiRNA,
or a UiRNA precursor such as an shRNA, is operably linked to a
promoter sequence that directs the transcription of the encoded
interfering RNA, or interfering RNA precursor, by an RNA
polymerase. Preferably, the promoter used in the UiRNA expression
cassette is inducible or derepressible and tightly regulated, such
that the expression of the UiRNA can be readily controlled. RNA
transcription cassettes and vectors suitable for use in the methods
of the present invention are known in the art and have been
described in a variety of references. For example, methods for the
in vivo expression of shRNAs are presented in U.S. Patent
Application Nos. 2003/0068821, 2003/0139363 and 2003/0144232, which
are incorporated herein by reference, in their entirety. Methods
for the stable expression of interfering RNAs have also been
described in papers by Brummelkamp, et al., (Science 296:550-553
(2002)), Paddison, et al., (Genes and Dev. 16:948-958 (2002)), Sui
et al., (Proc. Natl. Acad. Sci. U.S.A. 99:5515-5520 (2002)), and
Xia, et al., (Nucleic Acids Res. 31: e100 (2003)), which are all
incorporated herein by reference in their entirety. Additionally,
methods for the establishment of conditional transcription vectors
expressing interfering RNAs in mammalian cells were recently
described in a paper by Matsukura et al., (Nucleic Acids Res. 31:77
(2003)), which is also incorporated herein by reference in its
entirety. Finally, a chemical-regulated inducible interfering RNA
expression system that functions in plants has recently been
described in a paper by Guo, et al., (Plant J. 34:383-392 (2003)),
which is also incorporated herein by reference in its entirety.
[0098] General methods for the construction of such interfering RNA
transcription cassettes and vectors should be apparent to skilled
artisans apprised of the present invention. (See generally, Current
Protocols in Molecular Biology, Vol. 2, Ed. Ausubel, et al., Greene
Publish. Assoc. & Wiley Interscience, Ch. 13, 1988; Glover, DNA
Cloning, Vol. II, IRL Press, Wash., D.C., Ch. 3, 1986; Bitter, et
al., in Methods in Enzymology 153:516-544 (1987); The Molecular
Biology of the Yeast Saccharomyces, Eds. Strathern et al., Cold
Spring Harbor Press, Vols. I and II, 1982; and Sambrook et al.,
Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press,
1989.)
8. Gene Therapy Techniques
[0099] Generally, gene therapy techniques can be used to introduce
either the expression cassettes or vectors of the present invention
containing DNA sequences that direct the production of UiRNAs, or
their precursors, or both. Additionally, gene therapy techniques
can be used to introduce DNAs that direct the transcription of RNAs
(i.e., transcription cassettes) that either function as UiRNAs, or
serve as precursors (i.e., shRNAs) that are processed into UiRNAs
by cellular enzymes. In one set of embodiments, the levels of
expression of a plurality of gene products is manipulated in cells,
tissue, organisms or patients using UiRNAs targeted to the UtRNAs
residing in chimeric RNA transcripts transcribed from expression
cassettes introduced by a gene therapy approach. For example,
nucleic acids that direct the production of a plurality of chimeric
RNA transcripts encoding a plurality of gene products, or portions
or fragments thereof, and bearing a UtRNA, are introduced into
cells, tissues, organisms or patients such that the chimeric RNA
transcripts are expressed from expression cassettes provided by the
introduced nucleic acids. Subsequently, or simultaneously, UiRNAs
are introduced into the same cells, tissues, organisms or patients
by any of the means described above. These UiRNAs target the UtRNAs
of the chimeric RNA transcripts and reduce the expression of the
encoded gene product by directing the degradation of these
transcripts. For these purposes, nucleic acids encoding a
particular gene product, or portions or fragments thereof, and
bearing a UtRNA, especially a UtRNA located 3' of the coding
sequence, can be used in the gene therapy approaches in accordance
with the present invention. These embodiments are inherently useful
if manipulation of levels of expression of gene products encoded
by, and expressed from, transgenes is required. Additionally, in
cells, tissues, organisms or patients that naturally exhibit
transitive RNAi, or are made to exhibit transitive RNAi, the
methods of the present invention can also be used to reduce
expression from corresponding endogenous genes, and/or homologous
genes.
[0100] In cells, tissue, organisms and patients not exhibiting
transitive RNAi, the methods of the present invention can be used
for gene therapy as follows: if a disease-causing mutation exists
an organism or patient or in an endogenous protein gene in cells or
tissue in vitro, and if expression of a non-mutant form of that
gene product is desirable, then a nucleic acid bearing an
expression cassette that directs the production of a chimeric RNA
transcript, including the coding region for the non-mutant protein
and a UtRNA, can be introduced into the cells, tissues, organism or
patient. The expression cassette can then be used to produce a
chimeric RNA transcript within the cells, tissues or patient, and
the levels of expression of the non-mutant gene product from
chimeric RNA transcripts can be further manipulated, by the
introduction of UiRNA that is directed to the UtRNA of the chimeric
RNA transcripts. Advantageously, the expression cassette of the
present invention can be integrated into the genome, and perhaps
can be used to replace a corresponding defective endogenous gene
by, e.g., homologous recombination. See U.S. Pat. No. 6,010,908,
which is incorporated herein by reference. Alternatively, if the
disease-causing mutation is a recessive mutation, the expression
cassette is simply used to express a wild-type protein from a
chimeric RNA transcript, and levels of expression of the wild-type
protein can be manipulated as required by RNAi induced by
introduced UiRNAs that target a UtRNA in the chimeric RNA
transcript. In another embodiment, if the endogenous genes are
non-mutant but the level of expression of the protein encoded
thereby is desired to be increased, the expression cassette of the
present invention, encoding the same gene product and bearing a
UtRNA can be introduced into the patient by gene therapy. Once the
expression cassette of the present invention is introduced, the
level of expression of the desired gene product can be further
manipulated (i.e., "fine-tuned") by the introduction of UiRNAs
targeting the UtRNA borne by the chimeric RNA transcripts expressed
from the expression cassettes.
[0101] Various gene therapy methods are well known in the art.
Successes in gene therapy have been reported recently. See e.g.,
Kay et al., Nature Genet., 24:257-61 (2000); Cavazzana-Calvo et
al., Science, 288:669 (2000); and Blaese et al., Science, 270: 475
(1995); Kantoff, et al., J. Exp. Med. 166:219 (1987).
[0102] Any suitable gene therapy methods may be used for the
purposes of the present invention to direct the in vivo production
of chimeric RNA transcripts bearing UtRNAs and encoding desired
gene products. Generally, a nucleic acid encoding a desirable gene
product and a functionally linked UtRNA are incorporated into a
suitable expression vector and are operably linked to a promoter in
the vector. Suitable promoters include but are not limited to viral
transcription promoters derived from adenovirus, simian virus 40
(SV40) (e.g., the early and late promoters of SV40), Rous sarcoma
virus (RSV), and cytomegalovirus (CMV) (e.g., CMV immediate-early
promoter), human immunodeficiency virus (HIV) (e.g., long terminal
repeat (LTR)), vaccinia virus (e.g., 7.5K promoter), and herpes
simplex virus (HSV) (e.g., thymidine kinase promoter). Where
tissue-specific expression of the chimeric RNA transcript and
encoded gene product is desirable, tissue-specific promoters may be
operably linked to the exogenous gene. In addition, selection
markers may also be included in the vector for purposes of
selecting, in vitro, those cells that contain the exogenous gene.
Various selection markers known in the art may be used including,
but not limited to, e.g., genes conferring resistance to neomycin,
hygromycin, zeocin, and the like.
[0103] In one embodiment, an transcription cassette directing the
transcription of the UiRNA, or a precursor thereof, is incorporated
into a plasmid DNA vector, which is then introduced into target
cells, tissues, organisms or patients. Many commercially available
expression vectors may be useful for the present invention,
including, e.g., pCEP4, pcDNAI, pIND, pSecTag2, pVAX1, pcDNA3.1,
and pBI-EGFP, and pDisplay.
[0104] Various viral vectors may also be used for the methods of
the present invention. Typically, in a viral vector, the viral
genome is engineered to eliminate the disease-causing capability of
the virus, e.g., the ability to replicate in the target cells. The
exogenous nucleic acid to be introduced into cells or tissue in
vitro or into a patient may be incorporated into the engineered
viral genome, e.g., by inserting it into a viral gene that is
non-essential to viral infectivity. Viral vectors are convenient to
use as they can be easily introduced into cells, tissues and
patients by way of infection. Once in the host cell, the
recombinant viral genome is typically is integrated into the genome
of the host cell. In rare instances, the recombinant viral genome
may replicate autonomously and remain as an extrachromosomal
elements.
[0105] A large number of retroviral vectors have been developed for
gene therapy. These include vectors derived from oncoretroviruses
(e.g., MLV), lentiviruses (e.g., HIV and SIV) and other
retroviruses. For example, gene therapy vectors have been developed
based on murine leukemia virus (See, Cepko, et al., Cell,
37:1053-1062 (1984), Cone and Mulligan, Proc. Natl. Acad. Sci.
U.S.A., 81:6349-6353 (1984)), mouse mammary tumor virus (See,
Salmons et al., Biochem. Biophys. Res. Commun., 159:1191-1198
(1984)), gibbon ape leukemia virus (See, Miller et al., J.
Virology, 65:2220-2224 (1991)), HIV, (See Shimada et al., J. Clin.
Invest., 88:1043-1047 (1991)), and avian retroviruses (See Cosset
et al., J. Virology, 64:1070-1078 (1990)). In addition, various
retroviral vectors are also described in U.S. Pat. Nos. 6,168,916;
6,140,111; 6,096,534; 5,985,655; 5,911,983; 4,980,286; and
4,868,116, all of which are incorporated herein by reference.
[0106] Adeno-associated virus (AAV) vectors have been successfully
tested in clinical trials. See e.g., Kay et al., Nature Genet.
24:257-61 (2000). AAV is a naturally occurring defective virus that
requires other viruses such as adenoviruses or herpes viruses as
helper viruses. See Muzyczka, Curr. Top. Microbiol. Immun., 158:97
(1992). A recombinant AAV virus useful as a gene therapy vector is
disclosed in U.S. Pat. No. 6,153,436, which is incorporated herein
by reference.
[0107] Adenoviral vectors can also be useful for purposes of gene
therapy in accordance with the present invention. For example, U.S.
Pat. No. 6,001,816 discloses an adenoviral vector, which is used to
deliver a leptin gene intravenously to a mammal to treat obesity.
Other recombinant adenoviral vectors may also be used, which
include those disclosed in U.S. Pat. Nos. 6,171,855; 6,140,087;
6,063,622; 6,033,908; and 5,932,210, and Rosenfeld et al., Science,
252:431-434 (1991); and Rosenfeld et al., Cell, 68:143-155
(1992).
[0108] Other useful viral vectors include recombinant hepatitis
viral vectors (See, e.g., U.S. Pat. No. 5,981,274), and recombinant
entomopox vectors (See, e.g., U.S. Pat. Nos. 5,721,352 and
5,753,258).
[0109] Examples of viral vectors that have already been used to
express interfering RNAs within mammalian cells include retroviral
vectors, lentiviral vectors, adenoviral vectors and
adeno-associated viral vectors. The preparation use of these viral
vectors for deliver of interfering RNA into mammalian cells were
described, respectively, in papers by Barton and Medzhitov (Proc.
Natl. Acac. Sci., U.S.A. 99:14943-14945 (2002)), Matta et al.
(Cancer Biol. Ther. 2:206-210 (2003)), Arts et al., (Genome Res.
(E-published Sep. 15, 2003)) and Tomar et al. (Oncogene
22:5712-5715 (2003)), all of which are incorporated by reference
herein in their entirety.
[0110] Other non-traditional vectors may also be used for purposes
of this invention. For example, International Publication No. WO
94/18834 discloses a method of delivering DNA into mammalian cells
by conjugating the DNA to be delivered with a polyelectrolyte to
form a complex. The complex may be microinjected into or taken up
by cells.
[0111] The expression cassette encoding the chimeric RNA transcript
or the DNA sequence capable of directing the transcription of a
UiRNA, or a precursor thereof, or a plasmid DNA vector containing
such an expression cassette, may also be introduced into cells by
way of receptor-mediated endocytosis. See e.g., U.S. Pat. No.
6,090,619; Wu and Wu, J. Biol. Chem., 263:14621 (1988); Curiel et
al., Proc. Natl. Acad. Sci. USA, 88:8850 (1991). For example, U.S.
Pat. No. 6,083,741 discloses introducing an exogenous nucleic acid
into mammalian cells by associating the nucleic acid to a
polycation moiety (e.g., poly-L-lysine having 3-100 lysine
residues), which is itself coupled to an integrin receptor-binding
moiety (e.g., a cyclic peptide having the sequence
Arg-Gly-Asp).
[0112] Alternatively, the expression cassette encoding the chimeric
RNA transcript or the DNA sequence capable of directing the
transcription of a UiRNA, or a precursor thereof, or a plasmid DNA
vector containing such an expression cassette can also be delivered
into cells via amphiphiles. See e.g., U.S. Pat. No. 6,071,890.
Typically, the exogenous expression cassette, or a vector
containing it, forms a complex with the cationic amphiphile.
Mammalian cells contacted with the complex can readily take it
up.
[0113] The expression cassette encoding the chimeric RNA transcript
or the DNA sequence capable of directing the transcription of a
UiRNA, or a precursor thereof, or a DNA vector containing such an
expression cassette, can be introduced into cells or tissue in
vitro or in a patient for purposes of gene therapy by various
methods known in the art. For example, the expression cassette
alone or in a conjugated or complex form described above, or
incorporated into viral or DNA vectors, may be administered
directly by injection into an appropriate tissue or organ of a
patient. Alternatively, catheters or like devices may be used to
deliver exogenous gene sequences, complexes, or vectors into a
target organ or tissue. Suitable catheters are disclosed in, e.g.,
U.S. Pat. Nos. 4,186,745; 5,397,307; 5,547,472; 5,674,192; and
6,129,705, all of which are incorporated herein by reference.
[0114] In addition, the expression cassette encoding a chimeric RNA
transcript of the present invention, or a DNA sequence capable of
directing the expression of UiRNA, or a precursor thereof, or
vectors containing such expression cassettes, can be introduced
into isolated cells using any known techniques such as calcium
phosphate precipitation, microinjection, lipofection,
electroporation, biolystics, receptor-mediated endocytosis, and the
like. Cells containing the expression cassette and producing the
chimeric RNA transcripts of the present invention may be selected
and redelivered back to the patient by, e.g., injection or cell
transplantation. The appropriate amount of cells delivered to a
patient will vary with patient conditions, and desired effect,
which can be determined by a skilled artisan. See e.g., U.S. Pat.
Nos. 6,054,288; 6,048,524; and 6,048,729. Preferably, the cells
used are autologous, i.e., cells obtained from the patient being
treated.
9. Cell Models
[0115] In another aspect of the present invention, cell models are
provided in which the methods of the present invention are used to
manipulate the levels of expression of particular gene products
using UiRNAs directed at UtRNAs located within chimeric RNA
transcripts expressed within the cells. The cells can be cultured
and divided, and one half treated by introduction of UiRNA, while
the other half is sham treated. In this way the effects of
UiRNA-induced RNAi can be evaluated. Alternatively, cells
expressing the chimeric RNA transcripts of the present invention
can be compared with wild type cells under conditions in which
levels of expression of particular gene products are being
manipulated by the introduction of UiRNAs to both groups of cells.
Such cell models are useful tools for studying cellular functions
and biological processes associated with particular gene products,
as well as for detecting any off-target effects caused by
administration or introduction of UiRNA. Such cell models are also
useful tools for studying disorders and diseases associated with
the overexpression or underexpression of gene products, both mutant
and wild type, and can be used for testing various methods for
modulating cellular functions, or for treating the diseases and
disorders associated with aberrations in particular gene products
or aberrations in their expression levels. Importantly, the gene
products whose levels of expression are manipulated in such cell
models, need not be gene products from cellular genes, but may
include gene products from parasites and pathogens, including
viruses.
[0116] Advantageously, human cell models in which the methods of
the present invention are used to manipulate levels of gene
expression are provided in accordance with the present invention.
Such cell models may be established by isolating, from a patient,
wild type cells, or cells having an aberrant form of one or more
gene products, or cells exhibiting aberrant levels of expression of
one or more gene products. The isolated cells may be cultured in
vitro as a primary cell culture. Alternatively, the cells obtained
from the primary cell culture or directly from the patient may be
immortalized to establish a human cell line. Any methods for
constructing immortalized human cell lines may be used in this
respect. See generally Yeager and Reddel, Curr. Opini. Biotech.,
10:465-469 (1999). For example, the human cells may be immortalized
by transfection of plasmids expressing the SV40 early region genes
(See e.g., Jha et al., Exp. Cell Res., 245:1-7 (1998)),
introduction of the HPV E6 and E7 oncogenes (See e.g., Reznikoff et
al., Genes Dev., 8:2227-2240 (1994)), and infection with
Epstein-Barr virus (See e.g., Tahara et al., Oncogene, 15:1911-1920
(1997)). Alternatively, the human cells may be immortalized by
recombinantly expressing the gene for the human telomerase
catalytic subunit hTERT in the human cells. See Bodnar et al.,
Science, 279:349-352 (1998).
[0117] Alternatively, cell models may be established by isolating,
from an animal or a fungus, wild type cells, or cells having an
aberrant form of one or more gene products, or cells exhibiting
aberrant levels of expression of one or more gene products. The
isolated cells may be from any type of animal, including fungi,
nematodes, insects, and pathogenic protozoa. The isolated cells may
be cultured in vitro as a primary cell culture. Alternatively, the
cells obtained from the primary cell culture or directly from the
animal or fungi may be immortalized to establish a cell line. Any
methods for constructing immortalized cell lines may be used in
this respect.
[0118] Similarly, cell models may be established by isolating, from
a plant, wild type cells, or cells having an aberrant form of one
or more gene products, or cells exhibiting aberrant levels of
expression of one or more gene products. The isolated cells may be
from agriculturally important plants, such as cereal grain plants,
and other crop plants, including both monocots and dicots. The
isolated cells may be cultured in vitro as a primary cell culture.
Alternatively, the cells obtained from the primary cell culture or
directly from the plant may be immortalized to establish a plant
cell line. Any methods for constructing immortalized plant cell
lines may be used in this respect.
[0119] In alternative embodiments, cell models are provided by
recombinantly manipulating appropriate starting cells. The starting
cells may be bacterial cells, yeast cells, fungi cells, insect
cells, plant cells, animal cells, and the like. Advantageously, the
cells may be derived from mammals, most preferably humans. The
starting cells may be obtained directly from an individual, or a
primary cell culture, or preferably an immortal stable cell line.
In a preferred embodiment, human embryonic stem cells or
pluripotent cell lines derived from human stem cells are used as
target cells. Methods for obtaining such cells are disclosed in,
e.g., Shamblott, et al., Proc. Natl. Acad. Sci. USA, 95:13726-13731
(1998) and Thomson et al., Science, 282:1145-1147 (1998).
[0120] In one embodiment, a cell model is provided by recombinantly
expressing a gene product from the chimeric RNA transcripts of the
present invention (that also bear a UtRNA), in cells that do not
normally express such a gene product. For example, cells that do
not contain a particular gene product may be engineered to express
that particular gene product. Alternatively, cells that express a
mutant gene product may be engineered to express a corresponding
non-mutant gene product from a chimeric RNA transcript that also
bears a UtRNA. Simultaneously, or subsequently, UiRNAs can be
introduced into these engineered cells to reduce the level of
expression of the recombinantly expressed gene product. In a
specific embodiment, a particular human gene product is expressed
from chimeric RNA transcripts bearing UtRNAs in non-human cells.
The cell model may be prepared by introducing into target cells
nucleic acids containing the expression cassettes of the present
invention, and expressing the encoded gene products in the target
cells. For this purpose, the recombinant expression methods
described in Sections 3-6 may be used. In addition, the methods for
introducing nucleic acids into starting cells disclosed in the
context of gene therapy in Section 8 may also be used.
[0121] In another embodiment, a cell model recombinantly expressing
a particular gene product from the chimeric RNA transcripts of the
present invention is provided. The over-expression of a gene
product from the chimeric RNA transcripts of the present invention,
that also bear UtRNAs, may be achieved by introducing into starting
cells exogenous nucleic acids containing the expression cassettes
of the present invention, and selecting those cells that contain
the expression cassettes, produce the chimeric RNA transcripts, and
over-express the encoded gene products. The expression of the gene
products from the introduced exogenous nucleic acids may be
transient or, preferably stable, but can be manipulated by the
introduction of UiRNAs targeted to the UtRNAs in the recombinantly
expressed chimeric RNA transcripts. The recombinant expression
methods described in Section 3-6, and the methods for introducing
nucleic acids into starting cells disclosed in the context of gene
therapy in Section 8 may be used. Any cells may be employed for
establishing the cell model. Preferably, human cells lacking the
gene product whose expression levels are to be manipulated, or
having a normal concentration of the gene product, are used as
starting cells. The starting cells may be obtained directly from an
individual, or a primary cell culture, or preferably a stable
immortal human cell line. In a preferred embodiment, human
embryonic stem cells or pluripotent cell lines derived from human
stem cells are used as starting cells. Methods for obtaining such
cells are disclosed in, e.g., Shamblott, et al., Proc. Natl. Acad.
Sci. USA, 95:13726-13731 (1998), and Thomson et al., Science,
282:1145-1147 (1998).
9.1. Mammalian Cell Models:
[0122] In a preferred set of cell model embodiments, mammalian
cells are used as target cells for expression cassettes of the
present invention, and for studies in which the levels of
expression of particular gene products are manipulated. The
expression cassettes in these target cells direct the production of
chimeric RNA transcripts bearing a UtRNA and encoding a gene
product of interest. The chimeric RNA transcripts, in turn, direct
the concomitant expression of the gene product of interest,
however, the level of expression of the gene product of interest
can be manipulated by the introduction of UiRNA designed to target
the UtRNA borne by the chimeric RNA transcripts. For this purpose,
virtually any mammalian cells can be used as starting cells
including normal tissue cells, stable cell lines, and transformed
tumor cells. Conveniently, mammalian cell lines such as CHO cells,
Jurkat T cells, NIH 3T3 cells, HEK-293 cells, CV-1 cells, COS-1
cells, HeLa cells, VERO cells, MDCK cells, WI38 cells, and the like
are used. Advantageously, mammalian cells that have been
manipulated so as to enable the cells to conduct transitive RNAi
are used.
[0123] Several mammalian expression vectors suitable for directing
the expression of the chimeric RNA transcripts of the present
invention are well known in the art and many are commercially
available. These vectors typically contain a suitable promoter, a
multiple cloning site, a transcription termination signal and a
polyadenylation signal. Examples of suitable promoters for the
transcription of the chimeric genes in mammalian cells include
viral transcription promoters derived from adenovirus, simian virus
40 (SV40) (e.g., the early and late promoters of SV40), Rous
sarcoma virus (RSV), and cytomegalovirus (CMV) (e.g., CMV
immediate-early promoter), human immunodeficiency virus (HIV)
(e.g., long terminal repeat (LTR)), vaccinia virus (e.g., 7.5K
promoter), and herpes simplex virus (HSV) (e.g., thymidine kinase
promoter). Inducible promoters can also be used. Suitable inducible
promoters include, for example, the tetracycline responsive element
(TRE) (See Gossen et al., Proc. Natl. Acad. Sci. USA, 89:5547-5551
(1992)), metallothionein IIA promoter, ecdysone-responsive
promoter, and heat shock promoters. Suitable origins of replication
for the replication and maintenance of the expression vectors in
mammalian cells include, e.g., the Epstein Barr origin of
replication in the presence of the Epstein Barr nuclear antigen
(see Sugden et al., Mole. Cell. Biol., 5:410-413 (1985)) and the
SV40 origin of replication in the presence of the SV40 T antigen
(which is present in COS-1 and COS-7 cells) (see Margolskee et al.,
Mole. Cell. Biol., 8:2837 (1988)). Suitable selection markers
include, but are not limited to, genes conferring resistance to
neomycin, hygromycin, zeocin, and the like. Many commercially
available mammalian expression vectors may be useful for the
present invention, including, e.g., pCEP4, pcDNAI, pIND, pSecTag2,
pVAX1, pcDNA3.1, and pBI-EGFP, and pDisplay. The vectors can be
introduced into mammalian cells using any known techniques such as
calcium phosphate precipitation, lipofection, electroporation, and
the like.
[0124] Similarly, several mammalian transcription vectors suitable
for directing the transcription of the UiRNAs, or RNAs that are
processed into UiRNAs (i.e., shRNAs), of the present invention are
well known in the art and many are commercially available.
Preferably, these vectors contain an inducible or derepressible
promoter functionally linked to the UiRNA coding sequence, such
that expression of the UiRNA, or UiRNA precursor, is completely
absent in the absence of an inducing or derepressing signal, but is
present in the presence of an inducing or derepressing signal. In
one embodiment, the transcription vectors contain nucleotide
sequences that allow for integration of the vector, or some portion
thereof, into the genome of target cells. In another embodiment,
the vectors possess nucleotide sequences that result in
tissue-specific transcription, or in the ability to manipulate the
expression levels of the encoded UiRNAs, or UiRNA precursors. An
example of an inducible siRNA expression system that facilitates
tight control of specific gene silencing by RNAi in human cells was
recently described in a paper by Chen, et al., (Cancer Res.
63:4801-4804 (2003)), which is incorporated herein by reference in
its entirety.
[0125] Viral expression vectors, which permit introduction of
recombinant expression cassettes into cells by viral infection, can
also be used for the expression of the chimeric RNA transcripts as
described above. Viral expression vectors generally known in the
art include viral vectors based on adenovirus, bovine papilloma
virus, murine stem cell virus (MSCV), MFG virus, and retrovirus.
See Sarver, et al., Mol. Cell. Biol., 1: 486 (1981); Logan &
Shenk, Proc. Natl. Acad. Sci. USA, 81:3655-3659 (1984); Mackett, et
al., Proc. Natl. Acad. Sci. USA, 79:7415-7419 (1982); Mackett, et
al., J. Virol., 49:857-864 (1984); Panicali, et al., Proc. Natl.
Acad. Sci. USA, 79:4927-4931 (1982); Cone & Mulligan, Proc.
Natl. Acad. Sci. USA, 81:6349-6353 (1984); Mann et al., Cell,
33:153-159 (1993); Pear et al., Proc. Natl. Acad. Sci. USA,
90:8392-8396 (1993); Kitamura et al., Proc. Natl. Acad. Sci. USA,
92:9146-9150 (1995); Kinsella et al., Human Gene Therapy,
7:1405-1413 (1996); Hofmann et al., Proc. Natl. Acad. Sci. USA,
93:5185-5190 (1996); Choate et al., Human Gene Therapy, 7:2247
(1996); WO 94/19478; Hawley et al., Gene Therapy, 1:136 (1994) and
Rivere et al., Genetics, 92:6733 (1995), all of which are
incorporated by reference.
[0126] Generally, to construct a viral vector, a chimeric gene
according to the present invention can be operably linked to a
suitable promoter. The promoter-chimeric gene construct is then
inserted into a non-essential region of the viral vector, typically
a modified viral genome. This results in a viable recombinant virus
capable of expressing the fusion protein encoded by the chimeric
gene in infected target cells. Once in the host cell, the
recombinant virus typically is integrated into the genome of the
host cell. However, recombinant bovine papilloma viruses typically
replicate and remain as extrachromosomal elements.
9.2 Plant Cell and Tissue Models:
[0127] In another set of embodiments, the methods of the present
invention are conducted in plant cell and tissue systems. Methods
for producing chimeric RNA transcripts and expressing exogenous
proteins in plant cells and tissues are well known in the art.
Similarly, methods for introducing siRNAs into plant cells and
tissues are well known in the art. These methods include the direct
introduction of RNAs synthesized in vitro, as well as the
introduction of DNA transcription cassettes and vectors that direct
the in vivo production of RNAs. As described above, the RNAs
introduced or expressed can be double-stranded siRNAs, or hairpin
RNAs that can be processed into siRNAs in vivo, by cellular
enzymes. See generally, Weissbach & Weissbach, Methods for
Plant Molecular Biology, Academic Press, NY, 1988; Grierson &
Corey, Plant Molecular Biology, 2d Ed., Blackie, London, 1988. An
example of an tightly-regulated chemical-inducible siRNA expression
system that facilitates the expression of interfering RNAs in plant
cells was recently described in a paper by Guo, et al., (Plant J.
34:383-392 (2003)), which is incorporated herein by reference in
its entirety.
[0128] Recombinant virus expression vectors based on, e.g.,
cauliflower mosaic virus (CaMV) or tobacco mosaic virus (TMV) can
be also used. Alternatively, recombinant plasmid expression vectors
such as Ti plasmid vectors and Ri plasmid vectors are also useful.
The expression cassettes of the present invention directing the
production of chimeric RNA transcripts encoding a gene product of
interest (in the target RNA) and bearing a UtRNA can be
conveniently assembled in expression vectors and placed under
control of a viral promoter such as the 35S RNA and 19S RNA
promoters of CaMV or the coat protein promoter of TMV, or of a
plant promoter, e.g., the promoter of the small subunit of RUBISCO
and heat shock promoters (e.g., soybean hsp17.5-E or hsp17.3-B
promoters). Numerous other methods exist for introducing the
expression cassettes and transcription cassettes of the present
inventions into plant cells. The use of these methods for the
practice of the instant invention will be apparent to one of skill
in the art of manipulating gene expression in plant cells.
9.3 Insect Cell Models:
[0129] In addition, the methods of the present invention can also
be conducted in insect cells, e.g., Spodoptera frugiperda, Aedes
spp., and Anopheles spp. cells, using any system known in the art.
For example, baculovirus-based systems can be used to introduce the
expression cassettes of the present invention to S. frugiperda
cells. Expression vectors and target cells utilizing this system
are well known in the art and are generally available from various
commercial vendors. For example, nucleotide sequences encoding gene
products of interest functionally linked to UtRNAs can be
conveniently cloned into a non-essential region (e.g., the
polyhedrin gene) of an Autographa californica nuclear polyhedrosis
virus (AcNPV) vector and placed under control of an AcNPV promoter
(e.g., the polyhedrin promoter). The non-occluded recombinant
viruses thus generated can be used to infect target cells such as
Spodoptera frugiperda cells in which the chimeric genes are
expressed. See, for example, U.S. Pat. No. 4,215,051.
10. Cell-Based Assays
[0130] The cell models of the present invention containing an
expression cassette of the present invention are useful in
screening assays for identifying compounds useful in treating
diseases and disorders. In addition, they may also be used in in
vitro pre-clinical assays for testing compounds, such as those
identified in the screening assays of the present invention.
[0131] For example, cells may be treated with compounds to be
tested and assayed for the compound's activity. A variety of
parameters relevant to particularly physiological disorders or
diseases may be analyzed.
11. Transgenic Animals
[0132] In another aspect of the present invention, transgenic
non-human animals are created expressing chimeric RNA transcripts
encoding particular gene products in their subject RNA, and bearing
a UiRNA-targetable UtRNA. Animals of any species may be used to
generate the transgenic animal models, including but not limited
to, mice, rats, hamsters, sheep, pigs, rabbits, guinea pigs,
preferably non-human primates such as monkeys, chimpanzees,
baboons, and the like. Further, animals used to generate transgenic
animal models may be animals that serve as vectors or reservoirs
for infectious diseases that infect humans, or commercially
important animals or plants. These animals may be arthropods, such
as mosquitoes, fleas and ticks, or they may be from other taxonomic
groups of invertebrates or vertebrates.
[0133] In one embodiment, transgenic animals are made to express
chimeric RNA transcripts containing a UtRNA and a subject RNA
encoding a gene product whose expression levels are to be
manipulated. Over-expression of the gene products under study may
be directed in a cell type or tissue that normally expresses the
animal counterparts of such gene product. Consequently, the
concentration of the selected gene product will be elevated to
higher levels than normal. The level of expression can later be
reduced, if necessary, by the introduction of UiRNAs.
Alternatively, one or more gene products are expressed in tissues
or cells that do not normally express such gene products, and the
levels of expression of these gene products can be manipulated by
the introduction of UiRNA.
[0134] To achieve over-expression in transgenic animals, the
transgenic animals are made to contain exogenous nucleic acids in
the form of expression cassettes that ultimately direct the
production of the chimeric RNA transcripts of the present
invention. These chimeric RNA transcripts, in turn, are translated
to yield the gene product, or gene products, under study.
Preferably, the gene products encoded in the expression cassettes
are human gene products. Alternatively, the gene products can be
virulence factors of pathogenic organisms, or transmission factors
of a pathogenic organism's vector species. Such expression
cassettes, which direct the expression of the chimeric RNA
transcripts of the present invention, may include a native or
non-native promoter, and preferably an inducible, or derepressible
non-native promoter. If the expression of the chimeric RNA
transcripts is desired to be limited to a particular tissue, an
appropriate tissue-specific promoter may be used.
[0135] If a reduction of expression of the gene product under study
is desired, UiRNAs targeting the UtRNA can be introduced into, or
expressed within the transgenic animal bearing the expression
constructs of the present invention. Methods for the introduction
of in vitro synthesized UiRNAs, and for the in vivo transcription
of UiRNAs are described above. Other methods of deliver of UiRNAs
exist. The efficient delivery of siRNAs to organs of postnatal mice
has been achieved by high pressure tail vein injection (Lewis et
al., Nat. Genet. 32:107-108 (2002)). Lentiviral vectors directing
the transcription of interfering RNA and transgenically supplied
siRNA have been used successfully to affect a knockdown of gene
expression in mice, as described in publications by Tiscornia et
al. (Proc. Natl. Acad. Sci. U.S.A. 100:1844-1848 (2003)) and Hasuwa
et al., (FEBS Lett. 532:227-230 (2002), both of which are
incorporated herein by reference in their entirety.
[0136] In a specific embodiment, the transgenic animal is a
"knockout" animal wherein the endogenous gene encoding the animal
orthologue of the gene product under study is knocked out. The
reduced expression, or the controlled expression of the endogenous
orthologue, may be achieved by knocking out the endogenous gene
encoding the gene product under study, typically by homologous
recombination. Alternatively, mutations that can cause reduced
expression (e.g., reduced transcription and/or translation
efficiency, or decreased mRNA stability) may also be introduced
into the endogenous genes by homologous recombination. Genes
encoding ribozymes or antisense compounds specific to the mRNAs
encoding the gene product(s) under study may also be introduced
into the transgenic animal. In addition, genes encoding antibodies
or fragments thereof specific to the endogenous protein may also be
introduced into the transgenic animal. Generally, however, the
expression levels of a particular gene product under study are
reduced by the introduction of, or in vivo expression of UiRNAs
targeted to the UtRNAs born by the chimeric RNA transcript
expressed from the expression cassettes of the present invention.
In a specific embodiment, the lack of expression of the animal
orthologues of the gene product under study is complemented by
expression of an orthologous gene product encoded by a chimeric RNA
transcript of the present invention.
[0137] In an alternate embodiment, transgenic animals are made in
which the endogenous genes encoding the animal orthologues of the
gene product under study are replaced with the expression cassettes
of the present invention that direct the expression of chimeric RNA
transcripts bearing a UtRNA, and having nucleotide sequences
encoding orthologous human gene products.
[0138] In yet another embodiment, the transgenic animal of the
present invention expresses specific mutant forms of the gene
product under study. For this purpose, variants of the gene product
under study exhibiting altered activities or properties, and the
nucleic acid variants encoding such variant proteins, may be
obtained by random or site-specific mutagenesis. The transgenic
animal of the present invention may be made to express such protein
variants by modifying the endogenous genes. Alternatively, the
nucleic acid variants may be introduced exogenously into the
transgenic animal genome to express the protein variants therefrom.
In a specific embodiment, the exogenous nucleic acid variants are
derived from orthologous human genes and the corresponding
endogenous genes are knocked out.
[0139] Any techniques known in the art for making transgenic
animals may be used for purposes of the present invention. For
example, the transgenic animals of the present invention may be
provided by methods described in, e.g., Jaenisch, Science,
240:1468-1474 (1988); Capecchi, et al., Science, 244:1288-1291
(1989); Hasty et al., Nature, 350:243 (1991); Shinkai et al., Cell,
68:855 (1992); Mombaerts et al., Cell, 68:869 (1992); Philpott et
al., Science, 256:1448 (1992); Snouwaert et al., Science, 257:1083
(1992); Donehower et al., Nature, 356:215 (1992); Hogan et al.,
Manipulating the Mouse Embryo; A Laboratory Manual, 2nd edition,
Cold Spring Harbor Laboratory Press, 1994; and U.S. Pat. Nos.
4,873,191; 5,800,998; 5,891,628, all of which are incorporated
herein by reference. As mentioned above, methods for creating
transgenic mice expressing interfering RNAs have been described in
publications by Tiscornia et al. (Proc. Natl. Acad. Sci. U.S.A.
100:1844-1848 (2003)) and Hasuwa et al., (FEBS Lett. 532:227-230
(2002), both of which are incorporated herein by reference in their
entirety.
[0140] Generally, for the purposes of the present invention, the
founder lines may be established by introducing appropriate
exogenous nucleic acids into, or modifying an endogenous gene in,
germ lines, embryonic stem cells, embryos, or sperm which are then
used in producing a transgenic animal. The gene introduction may be
conducted by various methods including those described above. See
also, Van der Putten et al., Proc. Natl. Acad. Sci. USA,
82:6148-6152 (1985); Thompson et al., Cell, 56:313-321 (1989); Lo,
Mol. Cell. Biol., 3:1803-1814 (1983); Gordon, Transgenic Animals,
Intl. Rev. Cytol. 115:171-229 (1989); and Lavitrano et al., Cell,
57:717-723 (1989). In a specific embodiment, the exogenous gene is
incorporated into an appropriate vector, such as those described
above, and is transformed into embryonic stem (ES) cells. The
transformed ES cells are then injected into a blastocyst. The
blastocyst with the transformed ES cells is then implanted into a
surrogate mother animal. In this manner, a chimeric founder line
animal containing the exogenous nucleic acid (transgene) may be
produced.
[0141] Preferably, site-specific recombination is employed to
integrate the exogenous gene or expression cassette into a specific
predetermined site in the animal genome, or to replace an
endogenous gene or a portion thereof with the exogenous sequence.
Various site-specific recombination systems may be used including
those disclosed in Sauer, Curr. Opin. Biotechnol., 5:521-527
(1994); Capecchi, et al., Science, 244:1288-1291 (1989); and Gu et
al., Science, 265:103-106 (1994). Specifically, the Cre/lox
site-specific recombination system known in the art may be
conveniently used which employs the bacteriophage P1 protein Cre
recombinase and its recognition sequence loxP. See Rajewsky et al.,
J. Clin. Invest., 98:600-603 (1996); Sauer, Methods, 14:381-392
(1998); Gu et al., Cell, 73:1155-1164 (1993); Araki et al., Proc.
Natl. Acad. Sci. USA, 92:160-164 (1995); Lakso et al., Proc. Natl.
Acad. Sci. USA, 89:6232-6236 (1992); and Orban et al., Proc. Natl.
Acad. Sci. USA, 89:6861-6865 (1992).
[0142] The transgenic animals of the present invention may be
transgenic animals that carry a transgene in all cells or mosaic
transgenic animals carrying a transgene only in certain cells,
e.g., somatic cells. The transgenic animals may have a single copy
or multiple copies of a particular transgene.
[0143] The founder transgenic animals thus produced may be bred to
produce various offspring. For example, they can be inbred,
outbred, and crossbred to establish homozygous lines, heterozygous
lines, and compound homozygous or heterozygous lines.
12. Transgenic Plants
[0144] In another aspect of the present invention, transgenic
plants are created expressing chimeric RNA transcripts comprising a
subject RNA, which encodes a particular gene product, and a UtRNA.
Plants of any species, monocot or dicot, may be used to generate
the transgenic plant models. Such transgenic plant models may
include, but are not limited to, Arabadopsis thaliana, cereal and
other grain plants (e.g., maize, rice, barley and wheat), other
crop plants including vegetable plants, fruit trees, tuber yielding
plants (e.g., potatoes, sweet potatoes, and cassaya), tobacco,
ornamental plants, and the like.
[0145] Methods for the production of transgenic plants are well
known in the art. (See Jones & Sutton, eds. Plant Molecular
Biology: Essential Techniques, John Wiley & Sons, Ltd., London
(1997); Martinez-Zapater & Salinas, eds., Arabidopsis
Protocols, Methods in Molecular Biology, Volume 82, Humana Press,
Totowa, N.J. (1998); and Gilmartin & Bowler, eds. Molecular
Plant Biology, Vol. 1, Oxford University Press, London (2002).) For
example, the transgenic plants of the present invention can be
created through agrobacterium-mediated transformation, using Ti- or
Ri-plasmid into which the desired sequence is inserted. For the
purposes of the present invention, the expression cassettes of the
present invention that direct the expression of chimeric RNA
transcripts can be inserted into the Ti- or Ri-plasmids, which can
then be propagated in agrobacterium, and ultimately introduced into
a host plant by agrobacterium-mediated transformation.
Alternatively, the expression cassettes of the present invention
can be introduced directly into plant cells by biolystics (i.e.,
gene gun), or into plant cell sphereoplasts by electroporation.
[0146] Regardless of the means of introduction, the introduced
expression cassettes then direct the production of chimeric RNA
transcripts bearing a UtRNA and a subject RNA encoding a gene
product whose expression levels are to be manipulated. These
chimeric RNA transcripts can then be translated to direct the
overexpression of the gene product of interest. At some point in
time when a reduction of expression of the encoded gene product is
desired, a UiRNA can be introduced into, or synthesized within, the
cells or tissues of the transgenic plant. The UiRNA, which
corresponds in sequence to the UtRNAs of the chimeric RNA
transcripts, induces RNAi (also known as post-transcriptional gene
silencing, or PTSG in plants) by directing the degradation of the
chimeric RNA transcripts. In species that exhibit transitive RNAi,
secondary siRNAs produced during the initial, or primary RNAi
response can target transcripts of related sequence for
degradation, including transcripts produced from the plant's
corresponding endogenous gene(s) (i.e., endogenous
transcripts).
[0147] Particularly useful methods for producing transgenic plants
that can be used for practicing the methods of the present
invention have been described recently by Guo and coworkers (Guo,
et al., Plant J. 34:383-392 (2003)). In particular, Guo and
colleagues have developed a chemical-inducible Cre/loxP
recombination system to trigger the expression of an
intron-containing inverted-repeat inhibiting RNA plants. They have
demonstrated its use in producing transgenic Arabidopsis thaliana
and Nicotiana benthamiana plants, in which the in vivo
transcription of inhibiting RNAs is not only induced at will, but
is also stringently controlled. The methods presented can be used
for the present invention, by redesigning the expression system to
produce UiRNA, and preparing transgenic plants in which UiRNA
production is stringently controlled but inducible at will. These
transgenic plants, or tissues or cells isolated from them, can then
be transfected with the expression vectors of the present invention
that direct the expression of chimeric RNA transcripts bearing a
subject RNA, encoding the gene product of interest, and a UtRNA. In
such transfected transgenic plants, or plant tissues or cells,
induction of UiRNA expression will result in silencing of the gene
product encoded by the subject RNA through a primary RNAi response.
During this primary RNAi response, secondary siRNAs will be
produced that can affect a secondary, transitive RNAi of genes
comprising regions of homologous nucleotide sequence.
13. Arrays
[0148] In another aspect of the present invention, the methods
disclosed herein provide a strategy for the high throughput
analysis of gene function in transfected cells, especially in
transfected cells that either naturally exhibit, or are made to
exhibit, transitive RNAi. In such arrays, introduction of the UiRNA
initiates the RNAi-mediated destruction of the subject RNA carried
on the chimeric RNA transcript expressed from the resident
expression vector. Similarly, arrays of transfected or transgenic
tissues or organisms are contemplated, wherein the introduction of
the UiRNA to individual members of the array results in the
RNAi-mediated destruction of a distinct subject RNA. In this
manner, a plurality of genes can be subjected to RNA interference
at the same time, through the introduction of a single UiRNA.
Additionally, in order to prepare such arrays of cells, tissues, or
organisms, arrays of expression vectors, or viral delivery vectors
are also contemplated.
[0149] Preferably these arrays contain a plurality of addresses
characterized by their association with a distinct subject RNA,
whether that subject RNA is merely encoded within a naked DNA
expression vector, or is being expressed within a transfected cell,
tissue or organism. Preferably these arrays contain at least 2, 3,
4, 5, 6, 7, 8, 9, 10, 12, 16, 18, 24, 48, 96, 200, 500, 1000 or
more distinct addresses, each characterized by an association with
a distinct subject RNA.
13.1. Microarrays
[0150] In one embodiment, methods of the present invention provide
for transfection microarrays. As used herein, the term
"transfection microarray" refers to solid surface of at least 4
cm.sup.2, upon which a plurality of spots, each with a diameter of
at least 50 .mu.m, are printed and subsequently dried or congealed
in a defined regular grid pattern ("array"), where each spot
initially contains at least 0.5 nl of an aqueous mixture of a
nucleic acid, or nucleic acids, and a compound (e.g., gelatin) that
will create a protective but semipermeable matrix around the
nucleic acids when said matrix is dried or congealed, and where the
individual spots within the array are separated from each other by
at least 200 .mu.m. (For examples of transfection microarrays and
the methods by which they are prepared, refer to U.S. Pat. No.
6,544,790, which is incorporated by reference herein in its
entirety.)
[0151] The term "transfected cell microarray," as used herein,
refers to small clusters of at least 10 cells growing on the
surface of a previously prepared "transfection microarray," each
cluster of cells having been transfected by the nucleic acid or
nucleic acids originally contained within the matrix of the spot
upon which they grew. Said clusters of transfected cells may, or
may not, reside within a monolayer, or contiguous "lawn" of cells
in which the cells growing between transfected clusters are not
themselves transfected. (For examples of transfected cell
microarrays and the methods by which they are prepared, refer to
U.S. Pat. No. 6,544,790, which is incorporated herein by
reference.)
[0152] As used herein, the term "reverse transfection" refers to
the technique whereby nucleic acids, in the form of a transfection
microarray treated to facilitate transfection, are placed in a cell
culture container, into which living cells are subsequently
introduced and allowed to grow as a monolayer on the surface of the
transfection microarray, and whereby small clusters of cells
growing in direct contact with specific microarray spots take up
and become transfected with the specific nucleic acid, or nucleic
acids, contained within that particular microarray spot. (For
details on how reverse transfections are conducted, refer to U.S.
Pat. No. 6,544,790, which is incorporated herein by reference.)
[0153] Using the methods disclosed by Sabatini in U.S. Pat. No.
6,544,790, which is incorporated by reference herein in it
entirety, transfected cell microarrays can be created that are
suitable for inducing the silencing, or reduction of expression, of
large sets of gene products using a common UiRNA. Using a coated
glass slide, or other suitable solid substrate, that is printed
with sets of expression vectors, each vector containing an
expression cassette that directs the expression of a chimeric RNA
transcript comprising an subject RNA encoding a particular gene
product, and bearing a UtRNA, a living microarray of cell clusters
recombinantly expressing the gene products, can be generated. Once
generated, a UiRNA corresponding in sequence to the common UtRNA
can be introduced to the cells of the transfected cell microarray
to induce RNAi, to simultaneously reduce the expression of all gene
products encoded by the set of expression vectors.
[0154] Any cell type may be used to make such arrays, as long as it
can be efficiently transfected with an expression vector, and can
tolerate the introduction of UiRNA to induce RNAi. For the purpose
of these embodiments of the present invention, UiRNAs can be
introduced into the cells of the transfected cell microarrays by
any effective means. For example, UiRNAs synthesized in vitro can
be introduced by transfection using lipofectamine 2000 (Invitrogen,
Carlsbad, Calif.). Such in vitro-synthesized UiRNAs may be
single-stranded shRNAs, or double stranded siRNA duplexes. In an
alternative embodiment, the cells of the transfected cell
microarrays can also be transfected with transcription vectors that
direct the in vivo production of UiRNA. Alternatively, the cells
can be transgenic cells capable of regulated, inducible synthesis
of UiRNA upon treatment with an inducing agent. UiRNAs within such
cells may take the form of double-stranded siRNA duplexes, or
single stranded shRNAs.
[0155] In a preferred alternative embodiment, cells used to prepare
the transfected cell microarrays of the present invention are
modified in advance to contain an integrated inducible, or
derepressible, expression cassette, or cassettes, that can be made
to direct the synthesis of UiRNAs when provoked with a specific
signal. Such cells may express either a single-stranded shRNA that
is processed into a UiRNA by cellular nucleases, or two
single-stranded RNAs that anneal to form a UiRNA. The advantage of
such cells is that they are poised for induction of RNAi, and
minimal manipulation is required for them to begin expressing the
UiRNA that is targeted to the UtRNA of the chimeric RNA transcripts
produced by expression vectors subsequently introduced into the
cells. In particular, the methods described in a paper by Guo and
coworkers (Guo, et al., Plant J. 34:383-392 (2003)), which is
incorporated by reference herein in its entirety, can be used for
the practice of the present invention in plant cell
microarrays.
[0156] If the cells employed to make these transfected cell
microarrays exhibit transitive RNAi, secondary siRNAs generated
during the primary RNAi response (induced by the introduction of
UiRNAs), will direct the silencing of endogenously expressed gene
products that correspond in sequence to the recombinantly expressed
gene products encoded by the chimeric RNA transcripts expressed. As
indicated above, cells naturally exhibiting transitive RNAi can be
used to prepare such transfected cell microarrays, as well as cells
that are made to exhibit transitive RNAi.
[0157] In another set of embodiments, the living microarrays of
transfected cell clusters can be used to determine or confirm what
gene products are responsible for particular cellular functions,
such as the detoxification of specific toxicants, or the metabolism
of specific drugs. In these embodiments the set of DNAs inserted
into the expression cassettes of the present invention are
specifically chosen because of their suspected or known role in the
phenomenon under study. Generally for such purposes, two identical
microarrays of transfected cells are prepared and handled as a
matched set. Within each set, one array serves as the treated
experimental (test) array, while the other serves as a non-treated
control. In such a matched set, specific gene products are
overexpressed at defined locations or addresses within the arrays
by clusters of cells. Exposure of the test array to the toxicants
or drugs may occur before, after, or during the recombinant
expression of the gene products under study.
[0158] In a related set of embodiments, the living microarrays of
transfected cell clusters can be used to identify or confirm what
pathogen or host gene products are required for infection by
selected pathogenic agents, or what pathogen gene products
contribute most to infectivity or pathogenicity. For example, the
viral gene products required for viral infection, viral
replication, or viral egress, can be identified. Alternatively,
host cell gene products exploited by a pathogen to invade the host,
or responsible for a host's resistance to infection, can also be
identified.
[0159] Advantageously, the cells comprising living microarrays of
transfected cell clusters used in such studies need not be human
cells, mammalian cells or even animal cells. In fact, the cells
used can be isolated from vector species that serve as reservoirs
for infectious agents. For example, a living microarrays of
transfected mosquito cell clusters can be employed to study what
gene products are critical for the invasion or survival of a
particular pathogen in mosquitoes, and the gene products tested may
be host (mosquito) cell gene products, or pathogen (i.e.,
Plasmodium faciparum, dengue virus, West Nile virus) gene
products.
[0160] Additionally, the living microarrays of transfected cell
clusters expressing different gene products can be examined before,
after, and during the introduction of UiRNA, and can be screened
for clusters of cells that exhibit detectable differences from
other clusters of transfected cells in the same array, or from
non-transfected control cells in the same array. Alternatively, two
duplicate living microarrays of transfected cell clusters can be
prepared, and RNAi can be induced in one microarray by the
introduction of UiRNA, while the second microarray serves as a
non-treated, or sham-treated, control.
13.2. Macroarrays
[0161] Alternatively, macroarrays of cells transfected with the
expression cassettes of the present invention, or even macroarrays
of transgenic organisms bearing expression cassettes of the present
invention, can be prepared. In such macroarrays, the cells or
organisms at each separate address within the macroarray carry a
unique expression cassette of the present invention, that
expression cassette being capable of directing the expression of a
chimeric RNA transcript of the present invention. Given such
macroarrays, the methods of the present invention allow for the
ready manipulation of expression levels for all of the gene
products encoded in the chimeric RNA transcripts, by the
introduction of the same UiRNA to all addresses within the
macroarray.
[0162] Such macroarrays of transfected cells can be prepared in
multi-welled plastic containers, such as standard 6 well culture
plates, or 96 microwell plates, and any other readily-manipulated
configurations. The transfected cells in such macroarrays may be
grown in suspension, or in monolayer culture. The size and
configuration of such macroarrays will be optimally chosen
depending upon the number of cells required for subsequent assays,
and the number of gene products under investigation. Such
macroarrays can comprise 2, 3, 4, 6, 12, 18, 24, 48, 96, 120, 180,
240, 480, 960 or more clusters of transfected test cells.
[0163] For macroarrays of transgenic organisms, arrays can be
produced by arranging containers suitable for the culture of such
organisms, in a regular configuration with defined addresses. Such
arrays may consist of test tubes arranged in a rack, or culture
vessels (e.g., flower pots) arranged on a tray, and such arrays may
comprise 2, 3, 4, 6, 12, 18, 24, 48, 96, 120, 180, 240, 480, 960 or
more transgenic organisms.
[0164] In certain embodiments, a library of expression cassette can
be provided in which each expression cassette encodes a chimeric
RNA transcript as described above comprising a subject RNA operably
linked to a universal target RNA. The library should encode at
least 2, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 100, 200, 500, 100,
5000, 10,000, 20,000, 30,000, 50,000 different subject RNAs while
all chimeric transcripts encoded by the library have a common
universal target RNA (UtRNA). The subject RNAs may correspond to a
collection of genes of interest, e.g., a subset of genes of an
organism (e.g., virus, nematode, drosophila, animal or human), or
substantially all genes of an organism (e.g., virus, nematode,
drosophila, animal or human).
[0165] The expression cassettes in the library may be in expression
vectors (e.g., plasmid vector, viral vector, etc.) or simply in
linear strand DNA. In addition, the expression cassettes in the
library can be arranged in an addressable array (e.g., on a solid
support), and the identity of the subject RNA encoded by the
expression cassette in each addressable spot in the array can be
either known or unknown. Alternatively, the library is a mixture of
different expression cassettes encoding different chimeric RNA
transcripts.
[0166] In one embodiment, the arrayed library can be used to
produce an array of target cells as described elsewhere in the
present disclosure.
[0167] In another embodiment, the library in a mixture is
introduced into a plurality of cells or tissues or organisms to
produce a plurality of mixed target cells for expressing therein
the chimeric RNA transcripts. As such, upon inducing RNA
interference with a universal interfering RNA targeting the UtRNA
in the chimeric RNA transcripts, the phenotypes of each target cell
exhibited under certain conditions reflect the effect of the
subject RNA expressed in the target cell. Therefore, by identifying
and isolating the cells exhibiting the phenotypes of interest, the
identity of the subject RNA in the target cell can be determined
and the function of the corresponding gene can be deciphered.
Preferably, the library and the cells, tissues or organisms are
contacted in a ratio such that approximately each cell receives one
molecule of expression cassette. The cells can be physically
separated, e.g. by spreading onto a medium support, in a similar
manner to the method of cDNA library screening in bacteria or yeast
host cells. The target cells are then subject to RNA interference
with the universal interfering RNA described above, and also
subject to certain conditions. The cells exhibiting phenotypes of
interest upon RNA interference can be isolated and the expression
cassette contained therein is characterized thereby associating the
gene in the expression cassette with the cellular phenotype.
[0168] It is noted that in these embodiments, kits are also
contemplated including the library (arrayed or disarrayed) or
target cells (arrayed or disarrayed), and a universal interfering
RNA targeting the universal target RNA in the library (or a vector
expressing the interfering RNA), and optionally instructions for
using the kits in the manner described above.
[0169] In alternative embodiments, the host cells used in making
the target cells described above contain a transcription vector
expressing the universal interfering RNA, preferably under certain
inducing conditions. As such, the target cells are produced by
introducing the expression cassettes or library of expression
cassettes into the host cells. Each target cell produced in this
manner contain both the transcription vector for expressing the
universal interfering RNA and an expression cassette for expressing
a chimeric RNA transcript having a subject RNA operably linked to a
universal target RNA upon which the universal interfering RNA
targets. The nucleic acid in the transcription vector encoding the
universal interfering RNA can be integrated into the chromosome of
the target cells. Preferably, the nucleic acid in the transcription
vector or integrated in the chromosome is operably linked to an
inducible promoter such that the expression of the universal
interfering RNA is inducible under certain defined conditions. Any
inducible promoters known in the art may be used.
[0170] Thus, the present invention also encompasses a plurality of
target cells each expressing a chimeric RNA transcript that has a
subject RNA operably linked to a universal target RNA, wherein at
least 2, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 32, 48, 96, 200, 500,
1,000, 5,000, 10,000 or 30,000 or more of the plurality of target
cells have different subject RNAs, and wherein all of the plurality
of target cells have the same universal target RNA. In addition,
each of the plurality of the target cells expresses a universal
interfering RNA targeting the universal target RNA. Kits comprising
such plurality of target cells are also contemplated. The kits may
further comprise instructions for using the kits in the various
methods of the present invention.
14. Disease Applications
[0171] The methods of the present invention are useful for
investigating diseases and disorders characterized by altered
levels of expression of particular gene products, or involving the
expression of particular virulence or transmission factors of
pathogenic organisms. The methods are particularly useful in the
study of diseases that either (a) infect organisms that exhibit
transitive RNAi (e.g., plants), (b) require transmission through
vector species that exhibit transitive RNAi, or (c) are caused by
organisms that exhibit transitive RNAi (e.g., nematodes and
possibly pathogenic protozoa). In each of these scenarios, the
methods of the present invention can be used to manipulate the
levels of expression of host gene products, such as those host gene
products that are used by pathogens to recognize or invade target
cells (i.e., cell surface receptors). The methods of the present
invention can also be used to manipulate the levels of expression
of pathogen gene products, such as gene products that, when
expressed by pathogens, cause an increase in virulence of the
pathogen (i.e., virulence factors). Additionally, in scenarios
where a pathogen infects a transmission vector species, or
intermediate host, (i.e., Plasmodium spp. or Arboviruses in
mosquitoes), and the transmission vector or intermediate host
species is responsible for transmission of the pathogen to humans,
the methods of the present invention can be used to manipulate
levels of expression of pathogen gene products required for the
infection of the transmission vector, or transmission of the
pathogen from the intermediate host to humans (i.e., "transmission
factors"). When either the pathogen or intermediate host exhibits
transitive RNAi, the methods of the present invention can
potentially be used to reduce the expression levels of both
recombinantly expressed gene products, as well as the
corresponding, or homologous, endogenously expressed gene products,
as described above. In such cases the methods of the present
invention may provide a mechanism to block the infectious cycles of
pathogenic organisms before they infect their ultimate hosts.
[0172] Advantageously, the methods of the present invention can be
used to simultaneously investigate the involvement of numerous gene
products, of both host and pathogen, in the course of infection by
infectious disease agents. In order to conduct such investigations,
microarrays of transfected cells, or even macroarrays of transgenic
organisms, into which an expression cassette of the present
invention has been introduced, can be prepared. The expression
cassettes direct the production of chimeric RNA transcripts that
comprise a subject RNA, encoding a particular gene product under
study, and a UtRNA. When translated, the chimeric RNA transcripts
direct the overexpression of the particular inserted gene product.
When expression of the inserted gene product is to be reduced in
all members of the array, the same UiRNA is introduced into, or
transcribed within, the cells or organisms of the array. The UiRNA,
which corresponds in sequence to the common UtRNA incorporated into
the chimeric RNA transcripts, induces a primary RNAi response and
causes the selective degradation of the chimeric RNA transcripts in
the cells or organisms of the array. In cells or organisms that
naturally exhibit transitive RNAi, or are made to exhibit
transitive RNAi, secondary siRNAs produced during the primary RNAi
response correspond in nucleotide sequence to regions nearby the
UtRNA in the originally targeted chimeric RNA transcripts. These
secondary siRNAs can induce a secondary RNAi response, and promote
the degradation of the transgenically-expressed chimeric RNA
transcripts, as well as endogenous transcripts bearing homologous
nucleotide sequences. Consequently, introduction of UiRNAs in such
cells or organisms, whether synthesized in vitro or transcribed in
vivo, can lead to greatly reduced expression of the recombinantly
expressed, as well as endogenously expressed, gene product under
study. In essence, and with regard to the gene product under study
in that particular cluster of cells or organism in the array, the
result can be a silencing (functional knockdown or knockout), or at
least a partial reduction of expression of a particular gene
product. Consequently, the arrays described above can be used to
simultaneously investigate the role of a plurality of specific gene
products in all aspects of disease etiology, or in all stages in
the cycle of an infectious disease including pathogen invasion,
replication, egress and transmission to new hosts.
[0173] The diseases that can be studied by the methods of the
present invention include genetic disorders, metabolic disorders,
and infectious diseases caused by any class of pathogen, including,
e.g., viruses, bacteria, fungi and protozoa. These diseases may
affect humans or non-human animals, or may affect plants of any
variety.
[0174] Also, as described above, the methods of the present
invention can be used to study the infection of non-human
intermediate hosts or transmission vector species, such as those
arthropods that transmit infectious diseases to humans (e.g.,
mosquitoes, ticks, fleas, and the likes). For these studies, arrays
of transfected arthropod (i.e., mosquito) cells may be
employed.
[0175] The methods of the present invention can also be used to
study the gene products involved in the infection of plants by
various plant pathogens, including viruses, bacteria, fungi,
nematodes, and other plant pathogens. For these studies,
microarrays of transfected plant cells may be employed, or
macroarrays of transgenic plants may be used.
[0176] Advantageously, since plants exhibit transitive RNAi, the
methods of the present invention can be used to create and select
disease- or pathogen-resistant transgenic varieties, or
alternatively, can be used to develop new means to protect plants
from infection by pathogens. In a particularly preferred embodiment
of the present invention, a plurality of transgenic plants are
prepared, in which the subject RNAs of the chimeric RNA transcripts
correspond to mRNAs, or fragments of mRNAs obtained from, or
expressed by a particular plant pathogen. Upon introduction of the
UiRNA to these transgenic plants, preferably by the induction of in
vivo transcription of the UiRNA, a primary RNAi response will be
mounted. During this primary RNAi response, secondary siRNA with
nucleotide sequences corresponding to regions of the subject RNA
will be generated, within each plant. Since each transgenic plant
expresses a different chimeric RNA transcript with a distinct
subject RNA, a different set of secondary siRNAs, will made in each
plant. As concentration of secondary siRNAs nears its peak, the
plurality of transgenic plants can be exposed to the pathogen that
served as the original source of the subject RNAs. Those transgenic
plants containing certain preferred sets of secondary siRNAs should
be more resistant to the pathogen than those transgenic plants
containing sets of siRNAs which are ineffective at blocking
infection by the pathogen. The transgenic plants that are most
resistant to infection by the pathogen are selected and the subject
RNA expressed within them is identified. The subject RNA thus
identified corresponds to the pathogen mRNA, or mRNA fragment, that
should be specifically targeted by gene-specific siRNAs expressed
in subsequently produced disease-resistant, transgenic plants.
[0177] Such gene-specific siRNAs thus identified can be expected to
be especially effective against infection, if the pathogen under
study is a nematode. This is because nematodes have been shown to
(1) take up siRNAs from the food they eat, (2) amplify the
silencing signal, and (3) carry out transitive RNAi. Consequently,
the methods of the present invention are particularly well-suited
to identifying siRNAs that can be expressed within plant tissues
that will impart resistance to attack of these tissues by
nematodes. However, the methods of the present invention are
clearly not limited to developing nematode-resistant plants. Indeed
the subject RNAs of the chimeric RNA transcripts expressed within a
plurality of transgenic can correspond in sequence to RNAs from any
plant pathogen. And since siRNAs have recently been shown to
mediate the interference of viral DNA accumulation in Nicotiana
tabacum (Vanitharani et al., Proc. Natl. Acad. Sci. U.S.A.
100:9632-9636), the methods of the present invention will likely
prove useful in identifying siRNAs that, when expressed within
transgenic plants, impart resistance to viral infections.
[0178] Advantageously, the methods of the present invention also
can be used to create transgenic plants that are resistant to
infection by any number of pathogens. Specifically, once subject
RNAs from several different pathogens are identified that result in
the generation of secondary siRNAs effective in imparting
resistance to that pathogen, transgenic plants expressing several
different chimeric RNA transcripts, each with a different preferred
subject RNA, but the same UtRNA can be prepared.
[0179] Importantly, RNAi has now been documented in a large number
of human pathogens, including members of the family of flagellate
protozoa Trypanosomatidae (Robinson & Beverly. Mol. Biochem.
Parasitol. 128:217-228 (2003); Huynh et al., J. Biol. Chem. (Epub
Jul. 29, 2003); Tschudi et al., Methods 30:304-312 (2003)), the
parasitic flatworm Schistosoma mansoni (Boyle et al., Mol. Biochem.
Parasitol. 128:205-215 (2003)), and the human filarial nematode
parasite Brugia malayi (Aboobaker AND Blaxter Mol. Biochem.
Parasitol. 129:41-51 (2003). Furthermore, stable and heritable RNAi
has been achieved in the malaria vector mosquito Anopheles
stephensi (Brown et al., Nucleic Acids Res. 31:e5 (2003)), and
intravenous injection of siRNAs designed to silence a Plasmodium
berghei (mouse malaria) gene into the bloodstreams of mice,
affected the silencing of that gene within circulating malarial
parasites (Mohmmed et al., Biochem. Biophys Res. Commun.
309:506-511 (2003)). These studies, and studies like these, provide
support to the notion that the methods of the present invention can
be useful in developing novel approaches to utilize RNAi as a means
to combating the infectious diseases of humans. For example, as
described above, the methods of the present invention can be used
to simultaneously screen the effects of silencing a plurality of
genes from human pathogens, using a single UiRNA to affect the
silencing of all genes. In this fashion, specific genes from
important human pathogens can be identified as viable targets for
therapeutic gene-specific silencing by gene-specific interfering
RNAs.
[0180] Finally, a recent report by Vanitharani and coworkers (Proc.
Natl. Acad. Sci. U.S.A. 100:9632-9636 (2003)), which is
incorporated by reference in its entirety, documents the successful
siRNA-mediated suppression of gene expression in cultured plant
cells, and demonstrates that siRNAs can interfere with and suppress
the accumulation of a nuclear-replicated DNA virus. This report, in
conjunction with the previously described chemical-regulated
inducible RNAi system developed by Guo and colleagues (Guo, et al.,
Plant J. 34:383-392 (2003)), provide support to the notion that the
methods of the present invention can be useful in developing novel
approaches to utilize RNAi as a means to combating the infectious
diseases of plants.
15. Pharmaceutical Compositions and Formulations
[0181] In another aspect of the present invention, pharmaceutical
compositions are also provided containing the UiRNAs of the present
invention, or RNAs that are processed into UiRNAs by cellular
enzymes. The compositions are prepared as a pharmaceutical
formulation suitable for administration into a patient or infected
organism. Accordingly, the present invention also extends to
pharmaceutical compositions, medicaments, drugs or other
compositions containing one or more of the therapeutic agent in
accordance with the present invention.
[0182] For example, such therapeutic agents include, but are not
limited to, (1) double-stranded UiRNAs, (2) small single-stranded
hairpin RNAs that are processed into UiRNAs by cellular enzymes,
(3) DNA vectors that direct the transcription of double-stranded
UiRNAs, (4) DNA vectors that direct the transcription of small
single-stranded hairpin RNAs that are processed into UiRNAs by
cellular enzymes, (5) viral vectors that direct the transcription
of double-stranded UiRNAs, and (6) viral vectors that direct the
transcription of small single-stranded hairpin RNAs that are
processed into UiRNAs by cellular enzymes, etc.
[0183] The compositions are prepared as a pharmaceutical
formulation suitable for administration into a patient or infected
organism. Accordingly, the present invention also extends to
pharmaceutical compositions, medicaments, drugs or other
compositions containing one or more of the therapeutic agent in
accordance with the present invention.
[0184] In the pharmaceutical composition, an active compound
identified in accordance with the present invention can be in any
pharmaceutically acceptable salt form. As used herein, the term
"pharmaceutically acceptable salts" refers to the relatively
non-toxic, organic or inorganic salts of the compounds of the
present invention, including inorganic or organic acid addition
salts of the compound. Examples of such salts include, but are not
limited to, hydrochloride salts, sulfate salts, bisulfate salts,
borate salts, nitrate salts, acetate salts, phosphate salts,
hydrobromide salts, laurylsulfonate salts, glucoheptonate salts,
oxalate salts, oleate salts, laurate salts, stearate salts,
palmitate salts, valerate salts, benzoate salts, naphthylate salts,
mesylate salts, tosylate salts, citrate salts, lactate salts,
maleate salts, succinate salts, tartrate salts, fumarate salts, and
the like. See, e.g., Berge, et al., J. Pharm. Sci., 66:1-19
(1977).
[0185] For oral delivery, the active compounds can be incorporated
into a formulation that includes pharmaceutically acceptable
carriers such as binders (e.g., gelatin, cellulose, gum
tragacanth), excipients (e.g., starch, lactose), lubricants (e.g.,
magnesium stearate, silicon dioxide), disintegrating agents (e.g.,
alginate, Primogel, and corn starch), and sweetening or flavoring
agents (e.g., glucose, sucrose, saccharin, methyl salicylate, and
peppermint). The formulation can be orally delivered in the form of
enclosed gelatin capsules or compressed tablets. Capsules and
tablets can be prepared in any conventional techniques. The
capsules and tablets can also be coated with various coatings known
in the art to modify the flavors, tastes, colors, and shapes of the
capsules and tablets. In addition, liquid carriers such as fatty
oil can also be included in capsules.
[0186] Suitable oral formulations can also be in the form of
suspension, syrup, chewing gum, wafer, elixir, and the like. If
desired, conventional agents for modifying flavors, tastes, colors,
and shapes of the special forms can also be included. In addition,
for convenient administration by enteral feeding tube in patients
unable to swallow, the active compounds can be dissolved in an
acceptable lipophilic vegetable oil vehicle such as olive oil, corn
oil and safflower oil.
[0187] The active compounds can also be administered parenterally
in the form of solution or suspension, or in lyophilized form
capable of conversion into a solution or suspension form before
use. In such formulations, diluents or pharmaceutically acceptable
carriers such as sterile water and physiological saline buffer can
be used. Other conventional solvents, pH buffers, stabilizers,
anti-bacterial agents, ribonuclease inhibitors, surfactants, and
antioxidants can all be included. For example, useful components
include sodium chloride, acetate, citrate or phosphate buffers,
glycerin, dextrose, fixed oils, methyl parabens, polyethylene
glycol, propylene glycol, sodium bisulfate, benzyl alcohol,
ascorbic acid, and the like. The parenteral formulations can be
stored in any conventional containers such as vials and
ampoules.
[0188] Routes of topical administration include nasal, bucal,
mucosal, rectal, or vaginal applications. For topical
administration, the active compounds can be formulated into
lotions, creams, ointments, gels, powders, pastes, sprays,
suspensions, drops and aerosols. Thus, one or more thickening
agents, humectants, and stabilizing agents can be included in the
formulations. Examples of such agents include, but are not limited
to, polyethylene glycol, sorbitol, xanthan gum, petrolatum,
beeswax, or mineral oil, lanolin, squalene, and the like. A special
form of topical administration is delivery by a transdermal patch.
Methods for preparing transdermal patches are disclosed, e.g., in
Brown, et al., Annual Review of Medicine, 39:221-229 (1988), which
is incorporated herein by reference.
[0189] Subcutaneous implantation for sustained release of the
active compounds may also be a suitable route of administration.
This entails surgical procedures for implanting an active compound
in any suitable formulation into a subcutaneous space, e.g.,
beneath the anterior abdominal wall. See, e.g., Wilson et al., J.
Clin. Psych. 45:242-247 (1984). Hydrogels can be used as a carrier
for the sustained release of the active compounds. Hydrogels are
generally known in the art. They are typically made by crosslinking
high molecular weight biocompatible polymers into a network that
swells in water to form a gel like material. Preferably, hydrogels
is biodegradable or biosorbable. For purposes of this invention,
hydrogels made of polyethylene glycols, collagen, or
poly(glycolic-co-L-lactic acid) may be useful. See, e.g., Phillips
et al., J. Pharmaceut. Sci. 73:1718-1720 (1984).
[0190] The active compounds can also be conjugated, to a
water-soluble non-immunogenic non-peptidic high molecular weight
polymer to form a polymer conjugate. For example, an active
compound is covalently linked to polyethylene glycol to form a
conjugate. Typically, such a conjugate exhibits improved
solubility, stability, and reduced toxicity and immunogenicity.
Thus, when administered to a patient, the active compound in the
conjugate can have a longer half-life in the body, and exhibit
better efficacy. See generally, Burnham, Am. J. Hosp. Pharm.,
15:210-218 (1994). PEGylated proteins are currently being used in
protein replacement therapies and for other therapeutic uses. For
example, PEGylated interferon (PEG-INTRON A.RTM.) is clinically
used for treating Hepatitis B. PEGylated adenosine deaminase
(ADAGEN.RTM.) is being used to treat severe combined
immunodeficiency disease (SCIDS). PEGylated L-asparaginase
(ONCAPSPAR.RTM.) is being used to treat acute lymphoblastic
leukemia (ALL). It is preferred that the covalent linkage between
the polymer and the active compound and/or the polymer itself is
hydrolytically degradable under physiological conditions. Such
conjugates known as "prodrugs" can readily release the active
compound inside the body. Controlled release of an active compound
can also be achieved by incorporating the active ingredient into
microcapsules, nanocapsules, or hydrogels generally known in the
art.
[0191] Liposomes can also be used as carriers for the active
compounds of the present invention. Liposomes are micelles made of
various lipids such as cholesterol, phospholipids, fatty acids, and
derivatives thereof. Various modified lipids can also be used.
Liposomes can reduce the toxicity of the active compounds, and
increase their stability. Methods for preparing liposomal
suspensions containing active ingredients therein are generally
known in the art. See, e.g., U.S. Pat. No. 4,522,811; Prescott,
Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York,
N.Y. (1976).
[0192] The active compounds can also be administered in combination
with another active agent that synergistically treats or prevents
the same symptoms or is effective for another disease or symptom in
the patient treated so long as the other active agent does not
interfere with or adversely affect the effects of the active
compounds of this invention. Such other active agents include but
are not limited to anti-inflammation agents, antiviral agents,
antibiotics, antifungal agents, antithrombotic agents,
cardiovascular drugs, cholesterol lowering agents, anti-cancer
drugs, hypertension drugs, and the like.
[0193] Generally, the toxicity profile and therapeutic efficacy of
the therapeutic agents can be determined by standard pharmaceutical
procedures in cell models or animal models, e.g., those provided in
Section 9, 10, 11 and 13, above. As is known in the art, the LD50
represents the dose lethal to about 50% of a tested population. The
ED50 is a parameter indicating the dose therapeutically effective
in about 50% of a tested population. Both LD50 and ED50 can be
determined in cell models and animal models. In addition, the IC50
may also be obtained in cell models and animal models, which stands
for the circulating plasma concentration that is effective in
achieving about 50% of the maximal inhibition of the symptoms of a
disease or disorder. Such data may be used in designing a dosage
range for clinical trials in humans. Typically, as will be apparent
to skilled artisans, the dosage range for human use should be
designed such that the range centers on the ED50 and/or IC50, but
significantly below the LD50 obtained from cell or animal
models.
[0194] It will be apparent to skilled artisans that therapeutically
effective amount for each active compound to be included in a
pharmaceutical composition of the present invention can vary with
factors including but not limited to the activity of the compound
used, stability of the active compound in the patient's body, the
severity of the conditions to be alleviated, the total weight of
the patient treated, the route of administration, the ease of
absorption, distribution, and excretion of the active compound by
the body, the age and sensitivity of the patient to be treated, and
the like. The amount of administration can also be adjusted as the
various factors change over time.
EXAMPLES
[0195] The present invention is described in further detail by way
of the following illustrative examples. However, it is not intended
that the present invention be limited to the examples provided.
1. Determining What Regions of the West Nile Virus Genome Represent
the Best Target Sequences for an RNAi-Based Approach to Blocking
Viral Invasion, Replication, Packaging or Egress in the Mosquito
Vector, Aedes aegypti.
[0196] West Nile virus (WNV) belongs to the family Flaviviridae; a
family that comprises more than 60 viruses, many of which are
important human pathogens. WNV primarily infects birds, but
occasionally also infects humans and horses. Like denge virus, a
closely related fellow flavivirus, WNV is transmitted to humans by
the bite of the Aedes aegypti mosquito. Advantageously, A. aegypti
cells (ATCC CCL-125) can be grown in culture, and are susceptible
to WNV infection in vitro. WNV replicates in the cytoplasm of
infected cells and has a positive strand RNA genome of about 11 kb
that encodes a single polyprotein. These features make WNV a useful
model system with which to study all members of the family
Flaviviridae.
[0197] Recently, Caplen and colleagues at the National Institutes
of Health proposed that inhibition of viral gene expression within
an insect host could be used to block virus replication and
subsequent transmission of the pathogen to humans. Using Ades
albopictus C6/36 cells, and Semliki Forest virus replicons, Caplen
and coworkers demonstrated that dsRNA-triggered inhibition of gene
expression and viral replication could indeed be accomplished in
mosquito cells (Caplen et al., Mol. Ther. 6:243-(2002)).
[0198] The methods of the present invention can be applied in order
to determine which regions of the West Nile virus genome represent
the best sequences for an RNAi-based approach to blocking viral
invasion, replication, packaging or egress in the mosquito vector,
Aedes aegypti in an array-based approach as follows.
[0199] Prepare a set of expression vectors, each containing an
expression cassette that directs the expression of a chimeric RNA
transcript encoding a short polypeptide representing a specific
portion of about 10 to 20 amino acid residues of the West Nile
virus polyprotein, and a UtRNA. Preferably the set of vectors
direct the expression of a set of fusion proteins comprising
polypeptides that match the sequence of the viral polyprotein at
regularly spaced intervals, and a carboxyl-terminal c-myc epitope
tag. The set of expression vectors are designed to direct the
transcription of the encoded chimeric RNA transcripts in insect
cells, using appropriate promoter sequences, etc.
[0200] Using this set of expression vectors, and the techniques of
Sabatini disclosed in U.S. Pat. No. 6,544,790, prepare a matched
pair of microarrays of A. aegypti cells (ATCC CCL-125) wherein
specific clusters of cells are transfected with the various
expression vector in the set. After 12-48 hours, introduce a UiRNA
into the cells of one transfected cell microarray, and leave the
second transfected cell microarray as an untreated control. The
UiRNA will induce a primary RNAi response by targeting the UtRNA of
the chimeric RNA transcripts, but secondary siRNAs corresponding to
sequences in the viral genome will be generated by a secondary RNAi
response. After an additional 12-48 hours, expose the cells of both
transfected cell microarrays to West Nile virus suspended in the
culture medium. After 12-48 hours, observe the clusters of cells in
the two microarrays, and determine which cell clusters in either
microarray show no signs of infection by the virus. Cell clusters
that show no sign of infection in the UiRNA-treated microarray, but
are infected in the untreated microarray indicate cells in which
RNAi induced by specific secondary siRNAs effectively blocked viral
invasion, replication, packaging or egress. The address of the
cells within the microarray reveals what expression vector was used
for reverse transfection of those cells, and the viral sequence
contained within the expression cassette within the expression
vector corresponds to a preferred siRNA target sequence. If the
viral gene identity in the identified cells in not readily
apparent, isolate the cells and analyze the DNA in the expression
cassette to determine the identity of the gene.
2. Determining or Confirming What Drug Metabolizing Enzymes (DME)
are Responsible for the Detoxification of a Toxicant.
[0201] Prepare a set of expression vectors, each containing an
expression cassette that directs the expression of a chimeric RNA
transcript encoding a particular DME, and a UtRNA. Preferably the
set of vectors carry an inducible or derepressible promoter such
that the transcription of the encoded chimeric RNA transcripts can
be manipulated in human cells.
[0202] Using this set of expression vectors, and the techniques of
Sabatini disclosed in U.S. Pat. No. 6,544,790, prepare a matched
pair of microarrays of human cells wherein specific clusters of
cells are transfected with the various expression vector in the
set. After 12-48 hours, introduce a UiRNA into the cells of one
transfected cell microarray, and leave the second transfected cell
microarray as an untreated control. The UiRNA will induce an RNAi
response by targeting the UtRNA in all of the chimeric RNA
transcripts. After an additional 12-48 hours, expose the cells of
both transfected cell microarrays to a toxicant suspended in the
culture medium. After 12-48 hours, observe the clusters of cells in
the two microarrays, and determine which cell clusters in either
microarray are resistant to the toxicant. Cell clusters that are
resistant to the toxicant in the untreated control array, but show
signs of intoxication in the UiRNA-treated microarray, are cells
containing expression vectors encoding a DME that can catalyze the
detoxification of the toxicant under study.
[0203] All publications, patents and patent application
publications cited above are herein incorporated by reference to
the same extent as if each individual publication, patent or patent
application publication was specifically and individually indicated
to be incorporated by reference. The mere mentioning of the
publications and patent applications does not necessarily
constitute an admission that they constitute prior art to the
instant invention or application.
[0204] Although the foregoing invention has been described in some
detail by way of illustration and example for purposes of clarity
of understanding, it will be obvious that certain changes and
modifications may be practiced within the scope of the appended
claims.
* * * * *